GB2271111A - Quinazoline derivatives - Google Patents

Quinazoline derivatives Download PDF

Info

Publication number
GB2271111A
GB2271111A GB9320077A GB9320077A GB2271111A GB 2271111 A GB2271111 A GB 2271111A GB 9320077 A GB9320077 A GB 9320077A GB 9320077 A GB9320077 A GB 9320077A GB 2271111 A GB2271111 A GB 2271111A
Authority
GB
United Kingdom
Prior art keywords
alkyl
amino
methyl
formula
prop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9320077A
Other versions
GB9320077D0 (en
Inventor
Andrew John Barker
Francis Thomas Boyle
Laurent Francois And Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd, British Technology Group Ltd filed Critical Zeneca Ltd
Priority to MX9306034A priority Critical patent/MX9306034A/en
Publication of GB9320077D0 publication Critical patent/GB9320077D0/en
Publication of GB2271111A publication Critical patent/GB2271111A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Abstract

Quinazoline derivatives of the formula I <IMAGE> wherein R<1> is hydrogen or a defined substituent, e.g. amino, (1 - 4C) alkyl and (1 - 4C) alkoxy; R<2> is hydrogen, (1 - 4C) alkyl, which can be substituted by certain substituents (3 - 4C) alkenyl or (3 - 4C) alkynyl; Ar<1> is phenylene or a 5- or 6-membered aromatic heterocyclene ring; Ar<2> is optionally substituted phenyl or heteroaryl; and Q is a defined substituent e.g. nitro, cyano, carbamoyl, (1 - 4C) alkylsulphonyl and N,N-di-[(1 - 4C) alkylsulphamoyl; or pharmaceutically-acceptable salts thereof; are useful as anti-tumour agents.

Description

QUIN & OLINE DERIVATIVES This invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity. The invention includes quinazoline derivatives and processes for their manufacture, pharmaceutical compositions containing said quinazoline derivatives and the use of said quinazoline derivatives in the manufacture of medicaments for use in the production of an anti-tumour effect in a warm-blooded animal such as man.
One group of anti-tumour compounds comprises the antimetabolites, such as aminopterin and methotrexate, which are inhibitors of enzymes which utilise folic acid derivatives. A newer compound of this type which showed considerable promise in clinical trials is known as CB3717 and is described and claimed in United Kingdom Patent Specification No. 2065653B. Despite its promising activity against human breast, ovarian and liver cancer however, CB3717 shows symptoms of toxicity in humans, particularly in relation to the liver and kidney [Calvert, Alison, Harland, Robinson, Jackman, Jones, Newell, Siddik, Whiltshaw, HcElwain, Smith and Harrap, J. Clin.
Oncol., 1986, 4, 1245; Cantwell, Earnshaw and Harris, Cancer Treatment Reports, 1986, 70, 1335; Bassendine, Curtin, Loose, Harris and James, J. Hepatol., 1987, 4, 39; Vest, Bork and Hasen, Eur. J. Cancer Clin.
Oncol., 1988, 24, 201; Cantwell, Hacaulay, Harris, Kaye, Smith, Milsted and Calvert, Eur. J. Cancer Clin. Oncol., 1988, 24, 733; Ssa, Zucchetti, Ginier, Willems, D'Incalci and Cavalli, Eur. J.
Cancer Clin. Oncol., 1988, 24, 769]. Such adverse side effects are reduced in compounds in which the 2-amino substituent of CB3717 is either missing or is replaced by one of various alternative substituents as disclosed respectively in United Kingdom Patent Specification Nos. 2175903 and 2188319.
Compounds of the CB3717-type are believed to act as anti-tumour agents by inhibiting the enzyme thymidylate synthase, which enzyme catalyses the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis. The anti-tumour activity of CB3717 may be assessed in vitro by determining its inhibitory effect on that enzyme, and in cell cultures by its inhibitory effect on cancer cell lines such as the mouse leukaemia cell line L1210, the mouse lymphoma cell lines L5178Y TK-/- and L5178Y TK +/- and the human breast cancer cell line HCF-7.
Other compounds of the CB3717-type may therefore have their anti-tumour activity assessed and compared with that of CB3717 by their activity against, for example, the same enzyme and the same cancer cell lines.
Antimetabolites, such as aminopterin and methotrexate, which are inhibitors of enzymes which utilise folic acid derivatives, have also shown promise in the treatment of various allergic diseases such as allergic rhinitis, atopic dermatitis and psoriasis. The quinazoline derivatives of the present invention, being antimetabolites, are thus of value as therapeutic agents in the treatment of, for example, allergic conditions such as psoriasis.
Antimetabolites such as methotrexate have also shown promise in the treatment of various inflammatory diseases such as inflammation of the joints (especially rheumatoid arthritis, osteoarthritis and gout) and inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis) [Weinblatt et al., New England J. Med., 1985, 312, 818; Andersen et al., Ann. Internat. Med., 1985, 103, 489; Healey, Bull Rheum. Dis., 1986, 36, 1]. The quinazoline derivatives of the present invention are thus of value as therapeutic agents in the treatment of, for example, inflammatory conditions such as rheumatoid arthritis.
European Patent Application No. 0316657 (published 24 Hay 89) discloses a series of quinazoline derivatives which lack the amino acid residue of compounds of the CB3717-type. The disclosed compounds are reported to possess inhibitory activity against thymidylate synthase. Among the disclosed compounds are quinazoline derivatives wherein the amino acid residue of compounds of the CB3717-type is replaced by a residue derived from 5-aminotetrazole.
It is also known from European Patent Application No.
0365763 (published 02 May 90) that quinazoline derivatives of, for example, the CB3717-type, but wherein the amino acid residue, has been replaced by, for example, a halogeno, cyano or phenylsulphonyl residue, retain activity against thymidylate synthase and the L1210 cell-line.
Ve have now found that the quinazoline derivatives of the present invention possess CB3717-type activity.
According to the invention there is provided a quinazoline derivative of the formula I (set out hereinafter) wherein R1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di- [ (1-4C)alkylj amino, piperidino, morpholino, piperazin-l-yl, 4-[ (1-4C)alkyljpiperazin-1-yl, 4-[(2-4C) alkanoyl] piperazin-1-yl, hydroxy-1(1-4C) alkyl, (1-4C)alkoxy-(1-4C)alkyl, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-l(1-4C)alkyl]amino-(1-4C)alkyl, piperidino- ( 1-4C)alkyl, morpholino-( 1-4C)alkyl, piperazin-l-yl-(1-4C)alkyl, 4-[ (1-4C)alkyl]piperazin-1-yl-(1-4C)alkyl, 4-[(2-4C)alkanoyl]piperazin-l-yl-(1-4C)alkyl, N-[hydroxy-(2-4C)alkyl]amino-(l-4C)alkyl N-[hydroxy-(2-4C) alkyl]-N-(1-4C) alkylamino-(1-4C) alkyl, N,N-di-[hydroxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkoxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C) alkoxy-(2-4C) alkyl]-N-(1-4C) alkylamino-(1-4C) alkyl, N,N-di-[(1-4C)alkoxy-(2-4C)alkyljamino-(1-4C)alkyl, N-[(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, N-[(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, ,N-di-[(1-4C) alkylamino-(2-4C) alkyl] amino-(1-4C) alkyl, N-[di-(1-4C)alkylamino-(2-4C)alkyllamino-(1-4C)alkyl, N-[di-(1-4C) alkylamino-(2-4C) alkyl]-N-(1-4C) alkylamino-(1-4C) alkyl, N,N-di-[di-(1-4C) alkylamino-(2-4C) alkyl] amino-(1-4C) alkyl, (2-4C) alkanoyloxy-(1-4C) alkyl, carboxy-(2-4C) alkanoyloxy-(1-4C) alkyl, (1-4C)alkoxycarbonyl-(2-4C)alkanoyloxy-(1-4C)alkyl, hydroxy (2-4C)alkoxy-(1-4C)alkyl or (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl; the quinazoline ring may optionally bear at the 5-, 7- or 8-position one further substituent selected from halogeno, (1-4C)alkyl and (1-4C)alkoxy; R2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy (2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Arl is phenylene or a 5- or 6-membered aromatic heterocyclene ring which contains up to 3 heteroatoms selected from nitrogen and sulphur, each of which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy;; Ar2 is phenyl or heteroaryl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy; and Q is nitro, cyano, carbamoyl, sulphamoyl, (1-4C)alkoxycarbonyl, di- [ (1-4C)alkoxy] phosphoryl, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl, phenylthio, phenylsulphinyl, phenylsulphonyl, phenyl- ( 1-4C)alkylthio, phenyl-(1-4C)alkylsulphinyl, phenyl- ( 1-4C) - alkylsulphonyl, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, heteroaryl-( 1-4C)alkylthio, heteroaryl-(1-4C) alkylsulphinyl, heteroaryl-(1-4C) alkylsulphonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, N-(1-4C) alkylsulphamoyl, N,N-di-[(1-4C) alkyl] sulphamoyl, morpholinosulphonyl, piperidinosulphonyl, piperazin-1-ylsulphonyl or 4-(1-4C)alkylpiperazin-l-ylsulphonyl, and when Q is a group comprising a phenyl or heteroaryl group, said phenyl or heteroaryl group may optionally bear one substituent selected from halogeno, cyano, hydroxy, amino, (1-4C)alkyl and (1-4C)alkoxy; and wherein the heteroaryl group when Ar2 is heteroaryl, or the heteroaryl group when Q is a heteroaryl-containing group, is a 5- or 6-membered heteroaryl ring which contains 1 or 2 nitrogen heteroatoms and optionally contains a further heteroatom selected from nitrogen, oxygen and sulphur; or a pharmaceutically-acceptable salt thereof.
In a further embodiment of the invention there is provided a quinazoline derivative of the formula I as defined hereinbefore wherein, in addition, Q is 4-(1-4C)alkoxycarbonylpiperazin-1- ylsulphonyl, N- [amino- (2-4C) alkylj sulphamoyl, N-[(1-4C) alkylamino-(2-4C) alkyl] sulphamoyl, N-{di-[(1-4C) alkyl] amino (2-4C)alkyl)sulphamoyl, N-(1-4C)alkyl-N-[amino-(2-4C)alkyl]sulphamoyl, N-(1-4C) alkyl-N-[(1-4C) alkylamino-(2-4C) alkyl] sulphamoyl or N-(1-4C) alkyl-N-{di-[(1-4C) alkyl] amino-(2-4C) alkyl} sulphamoyl; or a pharmaceutically-acceptable salt thereof.
The chemical formulae referred to herein by Roman numerals are set out for convenience on a separate sheet hereinafter. In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. An analogous convention applies to other generic terms.
It will be observed that a quinazoline derivative of the invention may possess one or more asymmetric carbon atoms and it can therefore exist in racemic and optically active forms. It is to be understood that this invention encompasses a racemic form of the quinazoline derivative and any optically-active form thereof which possesses anti-tumour activity, it being a matter of common general knowledge how a racemic compound may be separated into its optically-active forms.
It will also be observed that a quinazoline derivative of the invention by virtue of the -CO-CH < group may exist in an enolic form or in an equilibrium mixture of the enolic and ketonic forms.
It is to be understood that this invention encompasses a compound of the invention, whether it is in an enolic form, a ketonic form or a mixture thereof, which possesses anti-tumour activity.
Within the present invention it is to be understood that a quinazoline derivative of the formula I may exhibit the phenomenon of tautomerism and that the formulae drawings presented within this specification can represent only one of the possible tautomeric forms.
It is to be understood that the invention encompasses any tautomeric form which possesses anti-tumour activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
It is also to be understood that certain quinazoline derivatives of the formula I can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess anti-tumour activity.
Suitable values for the generic radicals referred to above include those set out below.
A suitable value for R1 or R2 when it is (1-4C)alkyl, or for a (1-4C)alkyl substituent which may be present on the quinazoline ring, on Ar or Ar2 or on a phenyl-containing or heteroaryl-containing group in Q, is, for example, methyl, ethyl, propyl, isopropyl or butyl.
A suitable value for R1 when it is (1-4C)alkoxy, or for a (1-4C)alkoxy substituent which may be present on the quinazoline ring, on Arl or Ar2 or on a phenyl-containing or heteroaryl-containing group in Q, is, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy.
A suitable value for a halogeno substituent which may be present on the quinazoline ring, on Arl or Ar2 or on a phenylcontaining or heteroaryl-containing group in Q, is, for example, fluoro, chloro or bromo.
A suitable value for R1 when it is (1-4C)alkylamino is, for example, methylamino, ethylamino, propylamino or isopropylamino; when it is di-[(1-4C)alkyllamino is, for example, dimethylamino, N-ethyl-N-methylamino or diethylamino; when it is 4-1(1-4C)alkyllpiperazin-l-yl is, for example, 4-methylpiperazin-l-yl or 4-ethylpiperazin-1-yl; and when it is 4-[(2-4C)alkanoyli- piperazin-l-yl is, for example, 4-acetylpiperazin-1-yl or 4-propionylpiperazin- 1-yl.
A suitable value for R1 when it is hydroxy-(1-4C)alkyl is, for example, hydroxymethyl, l-hydroxyethyl, 2-hydroxyethyl or 3-hydroxypropyl; when it is (1-4C)alkoxy-(1-4C)alkyl is, for example, methoxymethyl, ethoxymethyl, l-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl or 3-methoxypropyl; when it is amino-(1-4C)alkyl is, for example, aminomethyl, l-aminoethyl, 2-aminoethyl or 3-aminopropyl; when it is (1-4C)alkylamino-(1-4C)alkyl is, for example, methylaminomethyl, ethylaminomethyl, l-methylaminoethyl, 2-methylaminoethyl, 2-ethylaminoethyl or 3-methylaminopropyl; and when it is di-[(1-4C)alkyl]amino-(1-4C)alkyl is, for example, dimethylaminomethyl, N-ethyl-N-methylaminomethyl, diethylaminomethyl, l-dimethylaminoethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl or 3-dimethylaminopropyl.
A suitable value for R1 when it is piperidino-(1-4C)alkyl is, for example, piperidinomethyl, l-piperidinoethyl, 2-piperidinoethyl or 3-piperidinopropyl; when it is morpholino-(1-4C)alkyl is, for example, morpholinomethyl, l-morpholinoethyl, 2-morpholinoethyl or 3-morpholinopropyl; when it is piperazin-l-yl-(1-4C)alkyl is, for example, piperazin-l-ylmethyl, l-(piperazin-l-yl)ethyl, 2-(piperazin-1-yl)ethyl or 3-(piperazin-1-yl)propyl; when it is 4-[(1-4C)alkyl]piperazin-l- yl-(1-4C)alkyl is, for example, 4-methylpiperazin-1-ylmethyl, 4-ethylpiperazi-1-ylmethyl, 1-(4-methylpiperazin-1-yl) ethyl, 2- (4-methylpiperazin-1-yl)ethyl or 2-(4-ethylpiperazin-1-yl)ethyl; and when it is 4-[(2-4C) alkanoyl] piperazin-1-yl-(1-4C) alkyl is, for example, 4-acetylpiperazin-1-ylmethyl, 1- (4-acetylpiperazin-1-yl) - ethyl, 2- (4-acetylpiperazin-1-yl) ethyl or 2-(4-propionylpiperazin-1-yl) ethyl.
A suitable value for R1 when it is N-[hydroxy-(2-4C) alkyl]amino-(1-4C)alkyl is, for example, N- (2-hydroxyethyl) - aminomethyl, N-(3-hydroxypropyl) aminomethyl, 1-[N-(2-hydroxyethyl) amino] ethyl, 2-[N-(2-hydroxyethyl) amino] ethyl or 3-[N-(2-hydroxyethyl)amino]propyl; when it is N-[hydroxy-(2-4C)- alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl is, for example, N-(2-hydroxyethyl)-N-methylaminomethyl, N-(3-hydroxypropyl)-Nmethylaminomethyl, N-(2-hydroxyethyl)-N-ethylaminomethyl, l-{N-(2-hydroxyethyl-N-methylamino]ethyl, 2-[N-(2-hydroxyethyl)-N- methylamino] ethyl, 2-[N-(3-hydroxypropyl)-N-methylamio] ethyl or 3-[N-(2-hydroxyethyl) -N-methylamino] propyl; and when it is N,N-di -[hydroxy-(2-4C) alkyl amino-(1-4C) alkyl is, for example, N,N-di-(2-hydroxyethyl)aminomethyl, N,N-di-(3-hydroxypropyl)aminomethyl, 1-[N,N-di-(2-hydroxyethyl)amino]ethyl, 2-[N,N-di-(2-hydroxyethyl0 amino] ethyl, 2-[N,N-di (3-hydroxypropyl)amino] ethyl or 3-[N,N-di-(2-hydroxyethyl0 amino] propyl.
A suitable value for R1 when it is N-[(1-4C) alkoxy- (2-4C)alkyl]amino-(1-4C)alkyl is, for example, N-(2-methoxyethyl)aminomethyl, N-(2-ethoxyethyl)aminomethyl, N-(3-methoxypropyl) aminomethyl, 1-[N-(2-methoxyethyl0 amino] ethyl, 2-[N-(2-methoxyethyl) amino] ethyl, 20[N-(2-ethoxyethyl) amino] ethyl, 2-[N-(3-methoxypropyl) amino] ethyl or 3-[N-(2-methoxyethyl) amino]propyl; when it is N-[(1-4C)alkoxy-(2-4C)alkyl]-N-(1-4C)alkyl- amino-(1-4C)alkyl is, for example, N-(2-methoxyethyl)-N-methyl aminomethyl, N- (3-methoxypropyl) -N-methylaminomethyl, N-(2-methoxyethyl)-N-ethylaminomethyl, 2-[N-(2-methoxyethyl)-Nmethylamino] ethyl or 3-[N-(2-methoxyethyl)-N-methylamino] propyl; and when it is N,N-di-[(1-4C) alkoxy-(2-4C) alkyl] amino-(1-4C) alkyl is, for example, N,N-di-(2-methoxyethyl)aminomethyl, N,N-di-(2-ethoxyethyl)aminomethyl, N,N-di-(3-methoxypropyl)aminomethyl, 2-[N,N-di-(2-methoxyethyl) amino] ethyl, 2-[N,N-di-(2-ethoxy ethyl) amino] ethyl, 2-[N,N-di-(3-methoxypropyl)amino]ethyl or 3-[N,N-di-(2-methoxyethyl)amino]propyl.
A suitable value for R1 when it is N-[ (1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl is, for example, N-(2-methylaminoethyl) aminomethyl, N-(2-ethylaminoethyl) aminomethyl, N-(3-methylaminopropyl)aminomethyl, l-[N-(2-methylaminoethyl)- amino]ethyl, 2- [N- (2-methylaminoethyl) amino] ethyl, 2- [N- (2ethylaminoethyl)amino]ethyl, 2-[N-(3-methylaminopropyl)amino]ethyl or 3-[N-(2-methylaminoethyl)amino]propyl; when it is N-[(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl is, for example, N- (2-methylaminoethyl) -N-methylaminomethyl, N-(3-methylaminopropyl)-N-methylaminomethyl, N-(2-methylaminoethyl) N-ethylaminomethyl, N-(2-ethylaminoethyl) -N-methylaminomethyl, 2-[(2-methylaminoethyl)-N-methylamino] ethyl, 2-[N-(3-methylaminopropyl)-N-methylamino]ethyl or 3-[N-(2-methylaminoethyl)-N- methylaminolpropyl; and when it is N,N-di-l(1-4C)alkylamino-(2-,4C)- alkyl] amino-(1-4C) alkyl is, for example, N,N-di-(2-methylaminoethyl) aminomethyl, N,N-di-(2-ethylaminoethyl) aminomethyl, N,Ndi-(3-methylaminopropyl)aminomethyl, 2-lN,N-di-(2-methylamino ethyl) amino] ethyl, 2-[N,N-di-(2-ethylaminoethyl)amino]ethyl 2-[N,N-di-(3-methylaminopropyl) amino] ethyl or 3-[N,N-di-(2methylaminoethyl)amino]propyl.
A suitable value for R1 when it is N-[di-(1-4C)alkyl- amino-(2-4C) alkyl] amino-(1-4C) alkyl is, for example, N-(2-dimethylaminoethyl)aminomethyl, N-(2-diethylaminoethyl)aminomethyl, N-(3dimethylaminopropyl)aminomethyl, 2-lN-(2-dimethylaminoethyl)- amino]ethyl, 2-[N-(3-dimethylaminopropyl)amino]ethyl or 3-[N-(2-dimethylaminoethyl)amino]propyl;; when it is N-[di-(1-4C) alkylamino-(2-4C) alkyl]-N-(1-4C) alkylamino-(1-4C) alkyl is, for example, N- (2-dimethylaminoethyl)-N-methylaminomethyl, N- (3-dimethylaminopropyl)-N-methylaminomethyl, N-(2-dimethylaminoethyl-N-ethylaminomethyl, N- (2-diethylaminoethyl) -N-methylaminomethyl, 2-lN-(2-dimethylaminoethyl)-N-methylamino]ethyl or 3-[N-(2-dimethylaminoethyl)-N-methylamino]propyl;; and when it is N,N-di-[di-(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl is, for example, N,N-di- (2-dimethylaminoethyl) aminomethyl, N,N-di-(2-diethylaminoethyl)aminomethyl, N,N-di- (3-dimethylamino- propyl)aminomethyl, 2-[N,N-di-(2-dimethylaminoethyl)amino]ethyl, 2-[N,N-di-(3-dimethylaminopropyl)aminolethyl or 3- [N,N-di- (2-dimethylaminoethyl) amino] propyl.
A suitable value for R1 when it is (2-4C)alkanoyloxy-(1-4C)alkyl is, for example, acetoxymethyl, propionyloxymethyl, l-acetoxyethyl or 2-acetoxyethyl; when it is carboxy-(2-4C)alkanoyloxy- ( 1-4C)alkyl is, for example, 2-carboxyacetoxymethyl, 3-carboxypropionyloxymethyl, 2-(2-carboxyacetoxy)ethyl or 2-(3-carboxypropionyloxy)ethyl; and when it is (1-4C)alkoxycarbonyl- (2-4C)alkanoyloxy- ( 1-4C)alkyl is, for example, 2-methoxycarbonylacetoxymethyl, 2-ethoxycarbonylacetoxymethyl, 3-methoxycarbonylpropionyloxymethyl, 2-(2-methoxycarbonylacetoxy)ethyl or 2-(3-methoxycarbonylpropionyloxy)ethyl.
A suitable value for R1 when it is hydroxy-(2-4C) alkoxy-(1-4C)alkyl is, for example, 2-hydroxyethoxymethyl, 3-hydroxypropoxymethyl or 2-(2-hydroxyethoxy)ethyl; and when it is (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl is, for example, 2-methoxyethoxymethyl, 2-ethoxyethoxymethyl, 3-methoxypropoxymethyl, 3-ethoxypropoxymethyl or 2-(2-methoxyethoxy)ethyl.
A suitable value for R2 when it is (3-4C)alkenyl is, for example, prop-2-enyl, but-2-enyl, but-3-enyl or 2-methylprop-2-enyl; when it is (3-4C)alkynyl is, for example, prop-2-ynyl or but-3-ynyl; when it is hydroxy-(2-4C)alkyl is, for example, 2-hydroxyethyl or 3-hydroxypropyl; when it is halogeno-(2-4C)alkyl is, for example, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 3-fluoropropyl, 3-chloropropyl or 3-bromopropyl; and when it is cyano-(1-4C)alkyl is, for example, cyanomethyl, 2-cyanoethyl or 3-cyanopropyl.
A suitable value for Arl when it is phenylene is, for example 1,3- or 1,4-phenylene.
A suitable value for Arl when it is a 5- or 6-membered aromatic (that is, fully unsaturated) heterocyclene ring which contains up to 3 heteroatoms selected from nitrogen and sulphur is, for example, thiophenediyl, pyridinediyl, pyrimidinediyl or thiazolediyl.
A suitable value for Ar2 when it is heteroaryl, or for the heteroaryl group when Q is a heteroaryl-containing group, is a 5- or 6-membered heteroaryl ring which contains 1 or 2 nitrogen heteroatoms and optionally contains a further heteroatom selected from nitrogen, oxygen and sulphur, for example, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl or thiadiazolyl. The heteroaryl group may be attached through any available position including through any available nitrogen atom and the heteroaryl group may bear a substituent on any available nitrogen atom.
A suitable value for Q when it is (1-4C)alkoxycarbonyl is, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl or tert-butoxycarbonyl; when it is di-1(1-4C)alkoxy]phosphoryl is, for example, dimethoxyphosphoryl, diethoxyphosphoryl, dipropoxyphosphoryl or dibutoxyphosphoryl; when it is (1-4C)alkylthio is, for example, methylthio, ethylthio, propylthio, isopropylthio or butylthio; when it is (1-4C)alkylsulphinyl is, for example, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl or butylsulphinyl; when it is (1-4C)alkylsulphonyl is, for example, methylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl or butylsulphonyl; when it is phenyl-(1-4C)alkylthio is, for example, benzylthio, phenethylthio or 3-phenylpropylthio; when it is phenyl-(1-4C)alkylsulphinyl is, for example, benzylsulphinyl, phenethylsulphinyl or 3-phenylpropylsulphinyl; when it is phenyl-(1-4C)alkylsulphonyl is, for example, benzylsulphonyl, phenethylsulphonyl or 3-phenylpropylsulphonyl; when it is N-(1-4C)alkylcarbamoyl is, for example, N-methylcarbamoyl, N-ethylcarbamoyl or N-propylcarbamoyl; when it is N,N-di-[(l-4C)alkyl]carbamoyl is, for example, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl or N,N-dipropylcarbamoyl; when it is N-(1-4C)alkylsulphamoyl is, for example, N-methylsulphamoyl, N-ethylsulphamoyl or N-propylsulphamoyl; when it is N,N-di[(1-4C)alkyl]sulphamoyl is, for example, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or dipropylsulphamoyl; and when it is 4-(1-4C)alkylpiperazin-1-ylsulphonyl is, for example, 4-methyl-, 4-ethyl- or 4-propylpiperazin1-ylsulphonyl.
A suitable value for Q when it is a heteroaryl (1-4C)alkylthio group is, for example, heteroarylmethylthio or 2-heteroarylethylthio; when it is a heteroaryl-(1-4C)alkylsulphinyl group is, for example, heteroarylmethylsulphinyl or 2-heteroarylethylsulphinyl; and when it is a heteroaryl-(1-4C)alkylsulphonyl group is, for example, heteroarylmethylsulphonyl or 2-heteroarylethylsulphonyl.
A suitable value for Q when it is 4-(1-4C)alkoxycarbonylpiperazin-1-ylsulphonyl is, for example, 4-methoxycarbonyl-, 4-ethoxycarbonyl-, 4-propoxycarbonyl-, 4-butoxycarbonyl- or 4-tertbutoxycarbonyl-piperazin-1-ylsulphonyl; when it is N-[amino-(2-4C)alkyl]sulphamoyl is, for example N-(2-aminoethyl)sulphamoyl or N-(3-aminopropyl)sulphamoyl); when it is N-[(1-4C)alkylamino-(2-4C)alkyl]sulphamo is, for example, N- (2-methylaminoethyl) sulphamoyl, N-(2-ethylaminoethyl)sulphamoyl or N-(3-methylaminopropyl)sulphamoyl; when it is N-(di-[ (1-4C)alkyl]amino-(2-4C)alkyl)sulphamoyl is, for example, N- (2-dimethylaminoethyl) sulphamoyl, N-(2-diethylaminoethyl)sulphamoyl or N-(3-dimethylaminopropyl)sulphamoyl; when it is N-(1-4C)alkyl-N lamino-(2-4C)alkyl]sulphamoyl is, for example, N-methyl-N-(2-aminoethyl)sulphamoyl or N-ethyl-N-(2-aminoethyl)sulphamoyl; when it is N- ( 1-4C) alkyl-N- [(1-4C)alkylamino-(2-4C)alkyl]sulphamoyl is, for example, N-methyl-N-(2-methylaminoethyl)sulphamoyl or N-ethyl-N-(2-methylaminoethyl)sulphamoyl; and when it is N-(1-4C)alkyl-N-(di-[(1-4C)alkyl]amino-(2-4C)alkyl)sulphamoyl is, for example, N-methyl-N- (2-dimethylaminoethyl) sulphamoyl or N-ethyl-N- (2-dimethylaminoethyl) sulphamoyl.
A suitable pharmaceutically-acceptable salt of a quinazoline derivative of the invention which is sufficiently basic is an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a quinazoline derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium or tetra(2-hydroxyethyl)ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, trimethylamine or tris-(2-hydroxyethyl)amine.
Particular compounds of the invention are, for example, quinazoline derivatives of the formula I wherein: (a) R1 is hydrogen, amino, methyl, ethyl or methoxy and the quinazoline ring may optionally bear one further substituent selected from fluoro, chloro, bromo, methyl and inethoxy; and R2, Ar1, Ar2 and Q have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention;; (b) R1 is hydroxymethyl, methoxymethyl, ethoxymethyl, aminomethyl, methylaminomethyl, ethylaminomethyl, dimethylaminomethyl, diethylaminomethyl, piperidinomethyl, morpholinomethyl, piperazin- 1-ylmethyl, 4-methylpiperazin- 1-ylmethyl, 4-acetylpiperazin-1-ylmethyl, N- (2-hydroxyethyl)aminomethyl, N-(2-hydroxyethyl)-N-methylaminomethyl, N,N-di-(2-hydroxyethyl)aminomethyl, N- (2-methoxyethyl) aminomethyl, N- (2-methoxyethyl) -N- methylaminomethyl, N,N-di- (2-methoxyethyl) aminomethyl, N- (2-methylaminoethyl) aminomethyl, N- (2-methylaminoethyl) -N- methylaminomethyl, N,N-di- (2-methylaminoethyl) aminomethyl, N-(2-dimethylaminoethyl)aminomethyl, N-(2-dimethylaminoethyl) N-methylaminomethyl, N, N-di- (2-dimethylaminoethyl) aminomethyl, 2-hydroxyethoxymethyl or 2-methoxyethoxymethyl, and the quinazoline ring may optionally bear at the 7-position one further substituent selected from fluoro, chloro and methyl; and R2, Ar1, Ar2 and Q have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; (c) R2 is hydrogen, methyl, ethyl, propyl, prop-2-enyl, prop-2 ynyl, 2-hydroxyethyl, 2-fluoroethyl, 2-bromoethyl or cyanomethyl; and R1, the quinazoline ring substituents, Ar1, Ar2 and Q have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; (d) Ar1 is 1,4-phenylene which may optionally bear one or two substituents selected from fluoro, chloro, bromo, hydroxy, amino, nitro, cyano, trifluoromethyl, methyl and methoxy, or Ar is thiophenediyl, pyridinediyl or thiazolediyl; and R, the quinazoline ring substituents, R2, Ar2 and Q have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; (e) Ar2 is phenyl which may optionally bear one or two substituents selected from fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, trifluoromethyl, methyl, ethyl and methoxy, or Ar2 is pyridyl, pyrimidinyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl or thiadiazolyl which may optionally bear one or two substituents selected from hydroxy, amino, nitro, cyano and methyl; and R1, the quinazoline ring substituents, R2, Ar1 and Q have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; (f) Q is nitro, cyano, carbamoyl, sulphamoyl, methoxycarbonyl, ethoxycarbonyl, dimethoxyphosphoryl, diethoxyphosphoryl, methylthio, ethylthio, propylthio, isopropylthio, butylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl, butylsulphinyl, methylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl, butylsulphonyl, phenylthio, phenylsulphinyl, phenylsulphonyl, benzylthio, benzylsulphinyl, benzylsulphonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N, N-dimethylcarbamoyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl, morpholinosulphonyl, piperidinosulphonyl, piperazin-l-ylsulphonyl or 4-methylpiperazin-1-ylsulphonyl, and when Q is a group comprising a phenyl group (such as phenyl or benzyl), said phenyl group may optionally bear one substituent selected from fluoro, chloro, cyano, methyl and methoxy; and R1, the quinazoline ring subsituents, R2, Ar and Ar2 have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; or (g) Q is nitro, cyano, carbamoyl, sulphamoyl, methoxycarbonyl, ethoxycarbonyl, dimethoxyphosphoryl, diethoxyphosphoryl, methylthio, ethylthio, propylthio, isopropylthio, butylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, isopropylsulphinyl, butylsulphinyl, methylsulphonyl, ethylsulphonyl, propylsulphonyl, isopropylsulphonyl, butylsulphonyl, phenylthio, phenylsulphinyl, phenylsulphonyl, benzylthio, benzylsulphinyl, benzylsulphonyl, pyridylthio, pyridylsulphinyl, pyridylsulphonyl, N-methylcarbamoyl, N-ethylcarbamoyl, N, N-dimethylcarbamoyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl, morpholinosulphonyl, piperidinosulphonyl, piperazin-1-ylsulphonyl, 4-methylpiperazin-l-ylsulphonyl, 4-tert-butoxycarbonylpiperazin-1-ylsulphonyl, N-(2-methylaminoethyl)- sulphamoyl, N-(2-dimethylaminoethyl)sulphamoyl, N-methyl-N- (2-methylaminoethyl) sulphamoyl or N-methyl-N-(2-dimethylaminoethyl)sulphamoyl, and when Q is a group comprising a phenyl group (such as phenyl or benzyl), said phenyl group may optionally bear one substituent selected from fluoro, chloro, cyano, methyl and methoxy; and R1, the quinazoline ring subsituents, R2, Arl and Ar2 have any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention; or a pharmaceutically-acceptable salt thereof.
A particular compound of the invention comprises a quinazoline derivative of the formula I wherein R1 is methyl, hydroxymethyl, methoxymethyl, methylaminomethyl, dimethylaminomethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl or 4-methylpiperazin-1-ylmethyl; the quinazoline ring may optionally bear a 7-fluoro, 7-chloro or 7-methyl substituent; R2 is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl; Ar1 is 1,4-phenylene which may optionally bear one fluoro substituent, or Ar1 is thiophene-2,5-diyl or thiazole-2,5-diyl with the group -CO-CH(Ar2) (Q) in the 2-position; Ar2 is phenyl which may optionally bear a substituent selected from fluoro, chloro, nitro, trifluoromethyl or methyl; and Q is nitro, cyano, carbamoyl, sulphamoyl, methoxycarbonyl, ethoxycarbonyl, dimethoxyphosphoryl, diethoxyphosphoryl, methylsulphinyl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphinyl, phenylsulphonyl, benzylsulphinyl, benzylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-methylsulphamoyl, N,Ndimethylsulphamoyl or morpholinosulphonyl; or a pharmaceutically-acceptable salt thereof.
A preferred compound of the invention comprises a quinazoline derivative of the formula I wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar1 is 1,4-phenylene or 2-fluoro-1,4-phenylene with the group -CO-CH(Ar2)(Q) in the l-position; Ar2 is phenyl which may optionally bear a 3-nitro substituent; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl or morpholinosulphonyl; or a pharmaceutically-acceptable salt thereof.
A further preferred compound of the invention comprises a quinazoline derivative of the formula I wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar1 is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group -CO-CH(Ar) (Q) in the 1-position) or pyridine-2,5-diyl (with the group -CO-CH(Ar) (Q) in the 2-position) ; Ar2 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-nitrophenyl, 4-cyanophenyl, 2-pyridyl or 3-pyridyl; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl, 4-pyridylsulphonyl, N-methylsulphamoyl, N, N-dimethylsulphamoyl, morpholinosulphonyl, piperazin-1-ylsulphonyl or N-methyl-N-(2-dimethylaminoethyl)sulphamoyl; or a pharmaceutically-acceptable salt thereof.
A further preferred compound of the invention comprises a quinazoline derivative of the formula I wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar1 is 1,4-phenylene or 2-fluoro-1,4-phenylene with the group -CO-CH(Ar2)(Q) in the 1-position; Ar2 is phenyl; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, N-methylsulphamoyl or N, N-dimethylsulphamoyl; or a pharmaceutically-acceptable salt thereof.
A further preferred compound of the invention comprises a quinazoline derivative of the formula I wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group -CO-CH(Ar) (Q) in the 1-position) or pyridine-2,5-diyl (with the group -CO-CH(Ar) (Q) in the 2-position) ; Ar2 is phenyl, 3-fluorophenyl, 4-fluorophenyl or 3-pyridyl; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl, 4-pyridylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl or morpholinosulphonyl; or a pharmaceutically-acceptable salt thereof.
A specific especially preferred quinazoline derivative of the invention includes, for example, the following quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof: - 4- [N-(2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl)amino]-a-methylsulphonyldesoxybenzoin, 4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2 ynyl)amino]-a-methylsulphonyldesoxybenzoin or N,N-dimethyl- -{p-EN-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylmethyl)-N-(prop-2-ynyl)amino]benzoyl}-a-toluenesulphonamide.
A further specific especially preferred quinazoline derivative of the invention includes, for example, the following quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof: - 4-[N-(2,7-dimethyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl)amino]-a-isopropylsulphonyldesoxybenzoin, N,N-dimethyl-p-fluoro-a-{2-lN-(2,7-dimethyl-4-oXo-3,4-dihydro- quinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl}- - toluenesulphonamide, 2,4'-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-a-methylsulphonyl- desoxybenzoin, N,N-dimethyl-p-fluoro-a-{o-fluoro-p-[N-(2,7-dimethyl-4- oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminolbenzoyl}-a- toluenesulphonamide, 4'-fluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)- N- (prop-2-ynyl) amino] -a-methylsulphonyldesoxybenzoin, 2,4'-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylmethyl) -N- (prop-2-ynyl)amino] -a-morpholinosulphonyldesoxybenzoin, &alpha;-[5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop2-ynyl)amino]pyridine-2-carbonyl}-E-fluoro-N,N-dimethyl-a- toluenesulphonamide or 4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N (prop-2-ynyl)amino]phenyl 1-methylsulphonyl- 1- (3-pyridyl)methyl ketone.
A compound of the invention comprising a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of structurally-related compounds. Such procedures are provided as a further feature of the invention and are illusrated by the following representative examples in which, unless otherwise stated, R1, R2, Ar1, Ar2 and Q have any of the meanings defined hereinbefore, provided that, when there is an amino, alkylamino, piperazin-1-yl, hydroxy or carboxy group in R, R, Ar, Ar or Q, any such group may optionally be protected by a conventional protecting group which may be removed when so desired by conventional means.
(a) The reaction of an acid of the formula II (set out hereinafter), or a reactive derivative thereof, wherein R3 is hydrogen 2 or a protecting group, with a compound of the formula Ar -CH2-Q.
A suitable reactive derivative of an acid of the formula II is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such as pentafluorophenol or an alcohol such as 1-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a carbodiimide such as dicyclohexylcarbodiimide.
The reaction is preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium, or a dialkylamino-lithium, for example lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo [5.4.0]undec-7-ene.The reaction is also preferably carried out in a suitable inert solvent or diluent, for example tetrahydrofuran, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulphoxide or acetone, and at a temperature in the range, for example, -78 to 150 0C, conveniently at or near ambient temperature.
A suitable value for R3 when it is a protecting group is, for example, a pivaloyloxymethyl group which may be removed by hydrolysis with a base, for example sodium hydroxide or ammonia, in a suitable inert solvent or diluent, for example methanol or ethanol.
A suitable protecting group for an amino, alkylamino or piperazin-1-yl group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for-example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
The starting materials of the formula II and of the formula Ar-CH2-Q may be prepared by standard procedures of organic chemistry.
The preparation of examples of such starting materials is described within the accompanying non-limiting Examples which are provided for the purpose of illustration only. Other necessary starting materials are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist. Thus, for example, the starting material of the formula II may be prepared by the reaction of a compound of the formula III wherein Z is a displaceable group, with an amine of the formula: HNR2-Arl-C02R4 4 wherein R4 is a protecting group which can be removed to provide a carboxylic acid.
A suitable value for the displaceable group Z is, for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, mesyloxy or 4-toluenesulphonyloxy group.
A suitable value for R4 is, for example, an alkyl group such as a methyl or ethyl group which may be removed by hydrolysis with a base such as sodium hydroxide, or R4 is a tert-butyl group which may be removed by cleavage with an acid, for example an organic acid such as trifluoroacetic acid. The protecting group R4 may be, for example an esterifying group which can be removed while the protecting group for any amino, alkylamino, hydroxy or carboxy group in R1, R2 and Ar is retained.
(b) The reaction of a compound of the formula III wherein R3 and Z have the meanings defined above, with an amine of the formula: HNR-Ar-CO-CH(Ar) (Q) The reaction is preferably carried out in the presence of a suitable base as defined above, in a suitable inert solvent or diluent as defined above, and at a temperature in the range, for example 250 to 150 C, conveniently at or near 90 C.
The starting materials of the formula III and of the formula: HNR-Ar-CO-CH (Ar) (Q) may be prepared by standard procedures of organic chemistry. The preparation of examples of compounds of the formula III is described within the accompanying non-limiting Examples which are provided for the purpose of illustration only. Other necessary starting materials are obtainable by analogous procedures to those described or by modifications thereto which are within the ordinary skill of an organic chemist.
(c) For the production of a compound of the formula I wherein Q is a group which comprises a sulphinyl or sulphonyl group, the oxidation of the corresponding compound of the formula I wherein Q is a group which comprises a thio group.
A suitable oxidising agent is, for example, any agent known in the art for the oxidation of thio to sulphinyl and/or sulphony, for example, hydrogen peroxide, a peracid (such as 3-chloroperoxybenzoic or peroxyacetic acid), an alkali metal peroxysulphate (such as potassium peroxymonosulphate), chromium trioxide or gaseous oxygen in the presence of platinum. The oxidation is generally carried out under as mild conditions as possible and with the required stoichiometric amount of oxidising agent in order to reduce the risk of over oxidation and damage to other functional groups. In general the reaction is carried out in a suitable solvent or diluent such as methylene chloride, chloroform, acetone, tetrahydrofuran or tert-butyl methyl ether and at a temperature, for example, at or near ambient temperature, that is in the range 15 to 35 0C. When a compound carrying a sulphinyl group is required a milder oxidising agent may also be used, for example sodium or potassium metaperiodate, conveniently in a polar solvent such as acetic acid or ethanol. It will be appreciated that when a compound of the formula I containing a suiphonyl group is required, it may be obtained by oxidation of the corresponding sulphinyl compound as well as of the corresponding thio compound.
(d) For the production of a compound of the formula I wherein R1 is amino-(1-4C)alkyl or substituted-amino-(1-4C)alkyl, the reaction of a compound of the formula I wherein R1 is hydroxy-(1-4C)alkyl, or a reactive derivative thereof, with ammonia or a substituted-amine.
A suitable reactive derivative of a compound of the formula I wherein R1 is hydroxy-(1-4C)alkyl is, for example, a compound of the formula I wherein R1 is a halogeno-(1-4C)alkyl or sulphonyloxy-(1-4C)alkyl group, for example a chloro-(1-4C)alkyl, mesyloxy-(1-4C)alkyl or a 4-toluenesulphonyloxy- ( 1-4C) alkyl group.
The reaction is preferably carried out in a suitable inert solvent or diluent, for example methanol, ethanol, tetrahydrofuran or N,N-dimethylformamide, and at a temperature in the range, for example, to to 1000C, conveniently at or near ambient temperature.
(e) For the production of a compound of the formula I wherein R1 is (2-4C)alkanoyloxy-( 1-4C)alkyl or substituted-(2-4C)alkanoyloxy (1-4C)alkyl, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of a compound of the formula I wherein R1 is hydroxy-(1-4C)alkyl with an acylating reagent.
A suitable acylating reagent is, for example, a (2-4C)alkanoyl or substituted (2-4C)alkanoyl halide (especially an appropriate alkanoyl chloride or bromide) or a corresponding anhydride.
The reaction is preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, chloroform, tetrahydrofuran or N,N0dimethylformamide, and at a temperature in the range, for example, 0 to 100 C, conveniently at or near room temperature.
(f) For the production of a compound of the formula I wherein Q is a piperazin-1-ylsulphonyl group, the cleavage of a compound of the formula I wherein Q is a 4-(1-4C)alkoxycarbonylpiperazin-l-yl group.
The cleavage conditions for the removal of the (1-4C)alkoxycarbonyl group necessarily vary with the nature of the (1-4C)alkyl group therein. Thus, for example, a (1-4C)alkyl group such as methyl or ethyl may be removed by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a (1-4C)alkyl group such as a tert-butyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid.
When a pharmaceutically-acceptable salt of a compound of the formula I is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure. When an optically active form of a compound of the formula I is required, it may be obtained by carring out one of the aforesaid processes using an optically active starting material, or by resolution of a racemic form of said compound using a conventional procedure.
As stated above a quinazoline derivative of the present invention possesses anti-tumour activity. This activity may be assessed, for example, using one or more of the procedures set out below: - (a) An in vitro assay which determines the ability of a test compound to inhibit the enzyme thymidylate synthase. Thymidylate synthase was obtained in partially purified form from L1210 mouse leukaemia cells and utilised using the procedures described by Jackman et al. (Cancer Res., 1986, 46, 2810 and Sikora et al., Biochem.
Pharmacol. 1988, 37, 4047); (b) An assay which determines the ability of a test compound to inhibit the growth of the leukaemia cell line L1210 in cell culture.
The test is similar to that described in UK Patent Specification No.
2065653B and has been described by Jones et al., J. Med. Chem., 1985, 28, 1468; (c) An assay which determines the ability of a test compound to inhibit the growth of the human breast cancer cell line HCF-7 in cell culture. The test is similar to that described by Lippman et al.
(Cancer Res., 1976, 36, 4595); and (d) An assay which determines the ability of a test compound to be cytotoxic to the lymphoma cell line L5178Y TK-/- in vitro. The lymphoma cell line L5178Y TK-/- is deficient in the enzyme thymidine kinase which phosphorylates thymidine and thus operates to generate a pool of thymidylate when de novo synthesis of thymidylate is prevented by the presence of an effective amount of an inhibitor of thymidylate synthase. The L5178Y TK-/- cell line is thereby more sensitive to the presence of an inhibitor of thymidylate synthase. [L5178Y TK-/- was obtained by mutation of the parent L5178Y cell line which is described by, for example, Fischer et al., Methods in Hedical Research, 1964, 10, 247].
Although the pharmacological properties of the quinazolines of the invention vary with structural changes, in general quinazolines of the invention possess activity in one or more of the above tests (a) to (d): Test (a) IC50 in the range, for example, 0.05-10 pM; Test (b) IC50 in the range, for example, 0.1-20 pM; Test (c) IC50 in the range, for example, 0.1-10 pM; Test (d) IC50 in the range, for example, 0.05-10 pM.
In general those quinazolines of the invention which are especially preferred possess activity in one or more of the above tests (a) to (d): Test (a) IC50 in the range, for example, 0.05-2 pM; Test (b) IC50 in the range, for example, 0.1-10 pM; Test (c) IC50 in the range, for example, 0.1-5 pM; Test (d) IC50 in the range, for example, 0.05-2 pM.
Thus, by way of example, the compound 4-[N-(2-methyl-4-oxo 3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino3-a-methyl- sulphonyldesoxybenzoin has an IC50 of 0.4pom in Test (a), an IC50 of ,1.2up in Test (b) and an IC50 of 0.7pM in Test (c); the compound 4-[N-(2,7-dimethyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl)aminol-a-methylsulphonyldesoxybenzoin has an IC50 of 0. 07pM in Test (a), an IC50 of -0.7 M in Test (b) and an IC50 of O.1pM in Test (c); and the compound N,N-dimethyl-cr-(E- [N-(2, 7-dimethyl-4-oxo-3, 4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoyl3-a- toluenesulphonamide has an IC50 of -0.08 M in Test (a), an IC50 0.56 pM in Test (b) and an IC50 of -0.3 M in Test (c).
A quinazoline derivative of the present invention may itself be active or it may be a pro-drug which is converted in vivo to an active compound.
A quinazoline derivative of the invention, or a pharmaceutically-acceptable salt thereof, may be administered to a warm-blooded animal, including a human, in the form of a pharmaceutical composition which comprises the quinazoline derivative, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
The composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution, emulsion or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients.
The composition may contain, in addition to the quinazoline derivative of the invention, one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; other antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example asparaginase; topoisomerase inhibitors, for example etoposide; and biological response modifiers, for example interferon.
The quinazoline will normally be administered to a warmblooded animal at a unit dose within the range 50-5000 mg per square metre body area of the animal, i.e. approximately 1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example, 1250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated.
Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
According to a further feature of the invention there is provided a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.
According to a further feature of the present invention there is provided a method for producing an anti-tumour effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the present invention, or a pharmaceutically-acceptable salt thereof.
The invention also provides the use of a quinazoline derivative of the present invention, or a pharmaceutically-acceptable salt thereof, in the manufacture of a novel medicament for use in the production of an anti-tumour effect in a warm blooded animal, such as man.
A quinazoline of the present invention is expected to possess a wide range of anti-tumour activities. CB3717 showed promising activity against human breast, ovarian and liver cancer and consequently it is expected that a quinazoline of the present invention will possess anti-tumour activity against these cancers. It is in addition expected that a quinazoline of the present invention will possess anti-tumour activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas. Such tumours require thymidine monophosphate as one of the essential nucleotides for the synthesis of cellular DNA. In the presence of an effective amount of a thymidylate synthase inhibitor such as an effective amount of a quinazoline of the present invention it is expected that tumour growth will be inhibited.
As previously mentioned a quinazoline derivative of the invention, or a pharmaceutically-acceptable salt thereof, is also of value in the treatment of, for example, allergic conditions such as psoriasis. In using a quinazoline of the invention for this purpose the compound will normally be administered at a dose within the range 50-5000 mg per square metre body area of the animal. In general for the treatment of an allergic condition such as psoriasis topical administration of a quinazoline of the invention is preferred. Thus, for example, for topical administration a daily dose in the range, for example, 1 to 50 mg/kg will be used.
The invention is illustrated but not limited by the following Examples in which unless otherwise stated: (i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration; (ii) operations were carried out at ambient temperature, that is in the range 18-200C and under an atmosphere of an inert gas such as argon; (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were preformed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 reverse-phase silica (Art. 9303) obtained from E.Merck, Darmstadt, Germany; (iv) yields are given for illustration only and are not necessarily the maximum attainable; (v) the end-products of the formula I have satisfactory microanalyses and their structures were confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra were determined using a Jeol FX 90Q or a Bruker AM200 spectrometer operating at a field strength of 200 MHz; chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (6 scale) and peak multiplicities are shown thus: s, singlet; d, doublet; d of d's, doublet of doublet's; t, triplet, m, multiplet; fast-atom bombardment (FAB) mass spectral data were obtained using a VG Analytical MS9 spectrometer and xenon gas and, where appropriate, either positive ion data or negative ion data were collected]; (vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, infra-red (IR) or NMR analysis; (vii) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, a Koffler hot plate apparatus or an oil-bath apparatus; and (viii) the following abbreviations have been used: ThF tetrahydrofuran; DMF N,N-dimethylformamide; DMA N,N-dimethylacetamide.
Example 1 n-Butyl lithium (1.sun in hexane, 2.34ml) was added dropwise to a stirred solution of di-isopropylamine (0.355g) in ThF (25ml) which had been cooled to -700C and the mixture was stirred at -70 C for 10 minutes. A solution of ethyl p-tolylacetate (0.568g) in THF (5ml) was added and the mixture was stirred at -700C for 30 minutes.
A solution of pentafluorophenyl E-(N- [2-methyl-4-oxo-3- (pivaloyloxy- methyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino}- benzoate (European Patent Application No. 0373891, Example 33 thereof; lg) in ThF (10ml) was added. The mixture was stirred at -700C for 1 hour and at ambient temperature for 2 hours. The mixture was poured into 1N aqueous hydrochloric acid solution and extracted with ethyl acetate (3 x 25ml). The combined extracts were washed with water (3 x 20ml) and with brine, dried (hgS04) and evaporated to leave a yellow oil. The acidity of the aqueous layer was reduced to pH5 by the addition of 1N aqueous sodium carbonate solution. The precipitate so obtained was isolated, washed with water and dried.The yellow oil and solid so obtained were combined and purified by column chromatography using increasingly polar mixtures of ethyl acetate and ethanol to give ethyl 2-IE-[N-(2-methyl-4-oxo-3,4- dihydroquinazolin-6-ylmethyl) -N- (prop-2-ynyl)amino] benzoyl) - 2-(p-tolyl)acetate as a gum which on trituration under diethyl ether gave a white solid (0.239g, 27X), m.p. 124-1260C.
Elemental Analysis : Found C, 72.1; H, 5.6; N, 8.2; C31H29N304 O.5H2O requires C, 72.1; H, 5.9; N, 8.2%.
Example 2 n-Butyl lithium (1.55M in hexane, 1.3ml) was added dropwise to a stirred solution of benzyl methyl sulphone (0.34g) in THF (47ml) which had been cooled to -700C. The mixture was stirred at -700C for 30 minutes. A solution of pentafluorophenyl E-(N- [2-methyl-4-oxo- 3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2- ynyl)amino)benzoate (0.627g) in THF (3ml) was added. The mixture was stirred at -700C for 1 hour and at ambient temperature for 16 hours.
The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water and with brine, dried (MgS04) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluent. There was thus obtained a white foam which, on trituration under diethyl ether, gave 4-[N-(2-methyl 4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino]-&alpha;- methylsulphonyldesoxybenzoin (0.187g, 37%), m.p. 144-147 C.
NHR Spectrum (CDC13 + CD3SOCD3) 2.46 (s, 3H), 2.51 (t, 1H), 3.01 (s, 3H), 4.24 (broad s, 2H), 4.78 (s, 2H), 6.20 (s, 1H), 6.8-7.5 (m, 5H), 7.6-8.0 (m, 6H), 8.04 (s, 1H).
Elemental Analysis: Found C, 64.1; H, 5.2; N, 7.8; C28H25N304S 1H20 requires C, 64.4; H, 5.8; N, 8.1X.
Example 3 Phenylnitromethane [Acta Chem. Scand. Ser. B, 1979, 33, 208; 0.301g] was added to a mixture of pentafluorophenyl E-(N-[2-methyl- 4-oXo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop- 2-ynyl)amino)benzoate (0.627g), triethylamine (1.38ml) and DMF (lOml) and the mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent. There was thus obtained 4-(N-[2-methyl4-oxo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop 2-ynyl)amino)-x-nitrodesoxybenzoin (0.069g).
A mixture of the product so obtained and a saturated solution of ammonia in methanol (10ml) was stirred at ambient temperature for 48 hours. The mixture was evaporated and the residue was triturated under diethyl ether. There was thus obtained 4-[N-(2-methyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl)amino]-a-nitrodesoxybenzoin (0.038g, 8X), m.p. 173-180"C.
NHR Spectrum (CD3SOCD3) 3.30 (t, 1H), 3.32 (s, 3H), 4.62 (d, 2H), 4.86 (s, 2H), 6.92 (d, 2H), 7.53 (t, 1H), 7.61 (m, 1H), 7.65 (d, 1H), 7.69 (m, 1H), 7.83 (d, 1H), 7.88 (d, 2H), 7.97 (d, 1H).
Elemental Analysis: Found C, 67.8; H, 5.1; N, 11.8; C27H22N404 0.5H20 requires C, 68.1; H, 4.8; N, 11.7.
Example 4 n-Butyl lithium (1.6M in hexane, 2.56ml) was added dropwise to a stirred solution of diethyl benzylphosphonate (0.912g) in ThF (40ml) which had been cooled to -70 C. The mixture was stirred at -7O0C for 5 minutes and at -40 C for 15 minutes. A solution of pentafluorophenyl E-(N-[2, 7-dimethyl-4-oxo-3- (pivaloyloxymethyl) - 3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino] benzoate (0.627g) in ThF (10ml) was added and the mixture was stirred at -60 C for 15 minutes and at ambient temperature for 1 hour. The mixture was acidified by the addition of glacial acetic acid.The mixture was evaporated and the residue was purified by reverse-phase column chromatography using decreasing polar mixtures of water, methanol and trifluoroacetic acid as eluent. There was thus obtained &alpha;-diethoxyphosphoryl-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin- 6-ylmethyl)-N-(prop-2-ynyl) amino] desoxybenzoin (0.148g, 26%), m. p.
190-196 C.
NNR Spectrum (CD3SOCD3) 1.09 (t, 6H), 2.36 (s, 3H), 2.44 (s, 3H), 3.19 (t, 1H), 3.86-4.01 (m, 4H), 4.32 (d, 2H), 4.72 (s, 2H), 5.61 (d, 1H), 6.77 (d, 2H), 7.21-7.38 (m, 3H), 7.45 (s, 1H), 7.52-7.59 (m, 2H), 7.67 (s, 1H), 7.92 (d, 2H).
Elemental Analysis : Found C, 58.8; H, 5.4; N, 6.5; C32H34N305P 0.5CF3C02H requires C, 59.2; H, 5.8; N, 6.2X.
The pentafluorophenyl - (N- [2, 7-dimethyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino)benzoate used as a starting material was obtained as follows: 2,6, 7-Trimethyl-3 , 4-dihydroquinazolin-4-one (European Patent Specification No. 0284338) was reacted with chloromethyl pivalate using the procedure described in European Patent Specification No. 0239362 for the corresponding reaction of 2,6-dimethyl-3,4dihydroquinazolin-4-one. There was thus obtained 3-(pivaloyloxymethyl)-2,6,7-trimethyl-3,4-dihydroquinazolin-4-one.
The product so obtained was reacted with N-bromosuccinimide in the presence of benzoyl peroxide using the procedure described in European Patent Specification No. 0284338 to give 6-bromomethyl-2,7dimethyl-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-4-one in 57% yield, m.p. 149-152 C.
The product so obtained was reacted with tert-butyl p- (prop-2-ynyl)aminobenzoate using an analogous procedure to that described in European Patent Application No. 0239362 to give p-[N-(2,7-dimethyl-4-oXo-3-pivaloyloxymethyl-3,4-dihydroquinazolin-6- ylmethyl)-N-(prop-2-ynyl)amino]benzoic acid in 70X yield, m.p. 226"C (decomposes).
The product so obtained was reacted with pentafluorophenol using an analogous procedure to that described in European Patent Application No. 0373891 for the corresponding 7-H compound. There was thus obtained the required starting material in 69Z yield, m.p. 168-171"C.
Example 5 n-Butyl lithium (1.6M in hexane, 0.79ml) was added dropwise to a stirred solution of benzyl methyl sulphone (0.216g) in ThF (15ml) which had been cooled to -700C. The mixture was stirred at -70 C for 30 minutes. A solution of pentafluorophenyl o-fluoro-p-{N-12,7- dimethyl-4-oxo-3- (pivaloyloxymethyl) -3, 4-dihydroquinazolin-6- ylmethyl]-N-(prop-2-ynyl)amino)benzoate (0.4g) in THF (5ml) was added.
The mixture was stirred at -70 C for 30 minutes and at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by column chromatography using a 1:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 2-fluoro-4-{N-[2,7-dimethyl-4-oxo-3-(pivaloyloxymethyl)-3,4 dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino]-&alpha;-methylsulphonyl- desoxybenzoin (0.185g).
A mixture of the product so obtained and a saturated solution of ammonia in methanol (10ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was purified by reverse phase column chromatography using decreasingly polar mixtures of water, methanol and trifluoroacetic acid as eluent.
There was thus obtained 2-fluoro-4-[N-(2,7-dimethyl-4-oxo-3,4 dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino]-&alpha;-methylsulphonyl- desoxybenzoin (0.061g, 40Z), m.p. 143-156"C.
NHR Spectrum (CD3SOCD3) 2.34 (s, 3H), 2.41 (s, 3H), 2.97 (s, 3H), 3.21 (t, 1H), 4.33 (d, 2H), 4.74 (s, 2H), 6.21 (s, 1H), 6.58 (m, 1H), 6.67 (m, 1H), 7.36-7.62 (m, 8H), 7.61 (t, 1H).
Elemental Analysis Found C, 56.2; H, 4.2; N, 6.2; C29H26FN304S 1.2CF3C02H requires C, 56.4, H, 4.1; N, 6.3Z.
The pentafluorophenyl o-fluoro-E-(N-[2, 7-dimethyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyll-N-(prop-2-ynyl)- amino)benzoate used as a starting material was obtained as follows: A mixture of 6-bromomethyl-2, 7-dimethyl-3-(pivaloyloxy- methyl)-3,4-dihydroquinazolin-4-one (0.9g), tert-butyl-o-fluoro-E (prop-2-ynyl)aminobenzoate [0.882g; prepared in 56Z yield by the reaction of tert-butyl p-amino-o-fluorobenzoate (European Patent Application No. 0373891) with propargyl bromide], potassium carbonate (0.691g), 18-crown-6 (0.005g) and N-methylpyrrolidin-2-one (20ml) was stirred and heated to 90"C for 6 hours.The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried (ngS04) and evaporated. The residue was purified by chromatography on silica gel using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent.
A mixture of the product so obtained (0.9g) and trifluoroacetic acid (20ml) was stirred at ambient temperature for 1 hour.
The mixture was evaporated and the residue was triturated under diethyl ether. There was thus obtained o-fluoro-p-{N-l2,7-dimethyl- 4-oxo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop2-ynyl)amino)benzoic acid as a solid (0.64g).
Elemental Analysis Found C, 64.7; H, 5.5; N, 8.2; C27H28FN305 O.1CF3C02H requires C, 64.7; H, 5.6; N, 8.3-X.
The product so obtained was reacted with pentafluorophenol using an analogous procedure to that described in European Patent Application No. 0373891 for the corresponding o-H, 7-H compound.
There was thus obtained the required starting material in 42% yield, m.p. 170-171"C.
Example 6 Using an analogous procedure to that described in Example 2, except that, where necessary, the appropriate pentafluorophenyl benzoate was used in place of pentafluorophenyl p-{N-[2-methyl-4-oxo- 3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2ynyl) amino} benzoate and the appropriate nucleophile was used in place of benzyl methyl sulphone there were obtained the quinazoline derivatives described in the following Table, the structures of which were confirmed by proton magnetic resonance and mass spectroscopy and by elemental analysis.
TABLE I
Example 6 Ra Q x m.p.
Compound No. ( C) 1a H cyano - 113-115 2 Me methylsulphonyl 0.5 236-242 3b Me isopropylsulphinyl 0.5 190-194 4c He isopropylsulphonyl 0.2 262-265 5d Me benzylsulphonyl 0.7 279-281 6e H N,N-dimethylsulphamoyl 0.4 122-124 7e,f Me N,N-dimethylsulphamoyl - 143-151 8g Me N-methylsulphamoyl - 134-153 gh Me morpholinosulphonyl 0.5 166-170 Notes a. The product was purified by reverse-phase chromatography using decreasingly polar mixtures of water, methanol and trifluoroacetic acid as eluent. The product so obtained contained 1.35 equivalents of trifluoroacetic acid.
b. The benzyl isopropyl sulphoxide used as a starting material was obtained as follows: a-Toluenethiol (12.4g) was added to a solution of sodium ethoxide obtained by the addition of sodium (2.3g) to ethanol (200ml)] and the mixture was stirred at ambient temperature for 5 minutes. Isopropyl bromide (12.3g) was added and the mixture was stirred at ambient temperature for 2 days. The mixture was evaporated and the residue was partitioned between ethyl acetate and 2N aqueous sodium hydroxide solution. The organic phase was washed with 2N aqueous sodium hydroxide solution and with water, dried (MgSO4) and evaporated. There was thus obtained benzyl isopropyl sulphide (22.lg).
A mixture of a portion (12.3g) of the product so obtained, 3-chloroperoxybenzoic acid (12.7g) and methylene chloride (500ml) was stirred at at OOC for 15 minutes and at ambient temperature for 2 hours. The mixture was filtered and the filtrate was evaporated.
The residue was purified by column chromatography using a 7:3 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained the required starting material (8.8g) as a solid.
c. The benzyl isopropyl sulphone used as the appropriate nucleophile was obtained as follows: A mixture of benzyl isopropyl sulphoxide (5g), 3-chloroperoxybenzoic acid (6.3g) and methylene chloride (100ml) was stirred at OOC for 15 minutes and at ambient temperature for 4 hours. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography using methylene chloride as eluent. There was thus obtained the required starting material (4.lg, 75), m.p. 65-66"C.
d. Lithium di-isopropylamide (prepared as described in Example 1) was used in place of n-butyl lithium to generate the lithium salt of dibenzyl sulphone.
The dibenzyl sulphone starting material was obtained as follows:- Benzyl bromide (11.96ml) was added to a solution of a-toluenethiol (12.4g) in 2N aqueous sodium hydroxide solution (100ml) and the mixture was stirred vigorously for 3 days at ambient temperature. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with 2N aqueous sodium hydroxide solution and with water, dried (NgS04) and evaporated.
There was thus obtained dibenzyl sulphide (22g).
A mixture of the product so obtained, 3-chloroperoxybenzoic acid (32.2g) and methylene chloride (400ml) was stirred at at O"C for 15 minutes and at ambient temperature for 3 hours. The mixture was filtered and the filtrate was washed with 2N aqueous sodium hydroxide solution, with water, with 2N aqueous hydrochloric acid and with brine, dried (NgS04) and evaporated. The residue was purified by column chromatography using methylene chloride as eluent. There was thus obtained the required starting material (12.1g), m.p.
148-149"C.
e. Lithium di-isopropylamide (2.2 equivalents) was used in place of n-butyl lithium to generate the lithium salt of N,N-dimethyl- -toluenesulphonamide.
The N,N-dimethyl-a-toluenesulphonamide used as a starting material was obtained as follows: A solution of a-toluenesulphonyl chloride (8.64g) in methylene chloride (20ml) was added dropwise to a vigorously stirred mixture of a 40% w/v solution of dimethylamine in water (80ml) and methylene chloride (1O0ml) which had been cooled to OOC. The mixture was stirred at ambient temperature for 2 hours. The organic layer was separated, dried(MgS04) and evaporated. The resultant solid was recrystallised from a 10:2:1 mixture of toluene, hexane and ethanol.
There was thus obtained the required starting material (5.84g, 65%), m.p. 98-100 C.
f. The product of the standard procedure was further purified by reverse-phase column chromatography using decreasingly polar mixtures of water, methanol and trifluoroacetic acid as eluent.
There was thus obtained the required product in 10% yield, which was shown by elemental analysis to be carrying 1.1 equivalents of trifluoroacetic acid: - Found C, 57.5; H, 5.1; N, 8.4; C30H30N404S 1.1CF3C02H requires C, 57.8; H, 4.7; N, 8.4%.
g. Three equivalents of the lithium salt of N-methyl-a-toluenesulphonamide were used. The product of the standard work-up procedure was further purified by reverse-phase column chromatography using decreasingly polar mixtures of water, methanol and trifluoroacetic acid as eluent. There was thus obtained the required product in 10X yield, which was shown. by elemental analysis to be carrying 1.45 equivalents of trifluoroacetic acid: Found C, 54.9; H, 4.6; N, 8.1; C29H28N404S 1.45CF3C02H requires C, 55.2; H, 4.2; N, 8.1%.
The N-methyl-a-toluenesulphonamide used as a starting material was obtained as follows: A solution of a-toluenesulphonyl chloride (3.59g) in methylene chloride (50ml) was added dropwise to a stirred mixture of a 33Z w/v solution of methylamine in ethanol (20ml) and methylene chloride (200ml) which had been cooled to 50C. The mixture was stirred at ambient temperature for 16 hours. The mixture was poured into water (200ml). The organic phase was washed with water and with brine, dried (MgS04) and evaporated. The resultant solid was recrystallised from a 4:1 mixture of hexane and ethyl acetate.
There was thus obtained the required starting material (1.49g).
Nirn Spectrum 2.69 (d, 3H), 4.10 (broad s, 1H), 4.25 (s, 2H), 7.39 (s, 5H).
h. Three equivalents of the lithium salt of benzyl morpholino sulphone were used, the salt being prepared by the addition of n-butyl lithium to a solution of the sulphone in ThF which had been cooled to -20 C. The mixture was stirred at -100 to -200C for 15 minutes and then cooled to -600C prior to the addition of the appropriate pentafluorophenyl ester.
The benzyl morpholino sulphone used as a starting material was obtained as follows: A solution of a mixture of morpholine (1.64g) and pyridine (1.49g) in methylene chloride (30ml) was added dropwise to a stirred solution of a-toluenesulphonyl choride (3.59g) in methylene chloride (50ml). The mixture was stirred at ambient temperature for 72 hours.
The mixture was washed in turn with water, with 2N aqueous hydrochloric acid and with water, dried (MgS04) and evaporated.
There was thus obtained the required sulphone (3.42g, 75X), m.p.
172-173"C (recrystallised from a 8:1 mixture of toluene and ethyl acetate).
Example 7 Using an analogous procedure to that described in Example 5, except that lithium di-isopropylamide (prepared as described in Example 1) was used in place of n-butyl lithium, benzyl phenyl sulphone (0.487g) was reacted with pentafluorophenyl p-{N-[2-methyl-4- oxo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2ynyl)amino)benzoate (0.627g) to give 4-(N-[2-methyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2- ynyl) amino}-&alpha;-phenylsulphonyldesoxybenzoin (0.295g).
Using an analogous procedure to that described in the second paragraph of Example 5, the pivaloyloxymethyl protecting group was removed from a portion (0.28g) of the material so obtained. There was thus obtained 4- [N- (2-methyl-4-oxo-3, 4-dihydroquinazolin-6- ylmethyl) -N- (prop-2-ynyl) amino 1 -a-phenylsulphonyldesoxybenzoin (0.166g), m.p. 141-151 C.
NER Spectrum (CD3SOCD3) 2.36 (s, 3H), 3.18 (t, 1H), 4.36 (t, 2H), 4.81 (s, 2H), 6.7-8.0 (m, 17H).
Elemental Analysis : Found C, 61.9; H, 4.3; N, 6.1; C33H27N3O4S l.lCF3C02H requires C, 61.5; H, 4.1; N, 6.1.
The benzyl phenyl sulphone used as a starting material was obtained as follows: A mixture of benzyl phenyl sulphide (lOg), 3-chloroperoxybenzoic acid (17.3g) and methylene chloride (300ml) was stirred at 0 C for 20 minutes and at ambient temperature for 4 hours. The mixture was extracted with 2N aqueous sodium hydroxide solution and with water. The organic phase was dried (MgS04) and evaporated. The solid residue was recrystallised from a mixture of hexane and ethyl acetate. There was thus obtained the required starting material (8.6g), m.p. 145-146 C.
Example 8 The procedure described in Example 2 was repeated except that methyl 3-nitrobenzyl sulphone was used in place of benzyl methyl sulphone. There was thus obtained 4-[N-(2-methyl-4-oxo-3,4 dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-a-methylsulphonyl- 3'-nitrodesoxybenzoin in 14% yield, m.p. 140-146"C.
NER Spectrum (CD3SOCD3) 2.36 (s, 3H), 2.97 (s, 3H), 3.05 (t, 1H), 4.42 (s, 2H), 4.87 (s, 2H), 6.8-8.65 (m, 11H).
Elemental Analysis : Found C, 59.8; H, 4.6; N, 8.8; C28H24N406S 0.6Et20. 0.4NaCl requires C, 59.7; H, 4.9; N, 9.2%.
The methyl 3-nitrobenzyl sulphone used as a starting material was obtained as follows: 3-Nitrobenzyl bromide (5.41g) was added portionwise to a stirred solution of sodium methanethiolate (1.94g) in DMF (20ml) and the mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic layer was washed with water, dried (ngS04) and evaporated to give methyl 3-nitrobenzyl sulphide (3.96g).
A solution of a portion (1.88g) of the sulphide so produced in methylene chloride (50ml) was added dropwise to a stirred solution of 3-chloroperoxybenzoic acid (7.44g) in methylene chloride (1O0ml) which had been cooled to 0 C. The mixture was stirred at ambient temperature for 16 hours. The mixture was washed with a saturated aqueous sodium bicarbonate solution, with a saturated aqueous sodium metabisulphite solution and with water, dried (MgS04) and evaporated.
There was thus obtained methyl 3-nitrobenzyl sulphone (2.05g, 93X), as an oil which was used without further purification.
Example 9 n-Butyl lithium (1.6M in hexane, 1.68ml) was added dropwise to a stirred solution of N,N-dimethyl-a-toluenesulphonamide (0.577g) in THF (20ml) which had been cooled to -70 C. The mixture was allowed to warm to -40 C and was stirred for 15 minutes. The mixture was recooled to -700C and a solution of pentafluorophenyl 2-(N-[2,7- dimethyl-4-oxo-3- (pivaloyloxymethyl) -3, 4-dihydroquinazolin-6- ylmethyl]-N-methylamino)benzoate (0.4g) in THF (4ml) was added. The mixture was stirred at -70 C for 30 minutes and at ambient temperature for 4 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluent.There was thus obtained N,N-dimethyl-&alpha;-[p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylmethyl)-N-methjylamino] benzoyl]-&alpha;-toluenesulphonamide (0.135g, 39%, m.p. 215-226 C.
MHR Spectres (CD3SOCD3) 2.29 (s, 3H), 2.41 (s, 3H), 2.60 (s, 6H), 3.16 (s, 3H), 4.72 (s, 2H), 6.53 (s, 1H), 6.71 (d, 2H), 7.36 (m, 3H), 7.42 (s, 1H), 7.48 (s, 1H), 7.71 (m, 2H), 7.93 (d, 2H).
The pentafluorophenyl E-(N-[2, 7-dimethyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-methylamino]benzoate used as a starting material was obtained as follows: A mixture of 6-bromomethyl-2, 7-dimethyl-3- (pivaloyloxy- methyl)-3,4-dihydroquinazolin-4-one (12g), p-methylaminobenzoic acid (5.4g), 2,6-lutidine (5g), sodium iodide (5mg) and DMF (175ml) was stirred and heated to 600C for 20 hours. The mixture was cooled and partitioned between diethyl ether and water. The organic phase was washed with water and with brine, dried (MgS04) and evaporated.
There was thus obtained a light brown solid (16.6g) which was used without further purification.
Pentafluorophenol (19.6g) and dicyclohexylcarbodiimide (16.5g) were added in turn to a solution of the product so obtained (16g) in DMF (380ml) which has been cooled in an ice-bath. The mixture was stirred at ambient temperature for 40 hours. The mixture was evaporated and the residue was purified by chromatography on silica gel using a 98.5:1.5 mixture of chloroform and methanol as eluent. There was thus obtained a light brown solid which was triturated under diethyl ether to give the required starting material (13.55g).
Example 10 n-Butyl lithium (1.5M in hexane, 2.8ml) was added dropwise to a stirred solution of p-fluorobenzyl morpholino sulphone (lug) in THF (40ml) which had been cooled to -40 C. The mixture was stirred at -40 C for 30 minutes. A solution of pentafluorophenyl -[N-(2- acetoxymethyl-7-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N (prop-2-ynyl)amino]-o-fluorobenzoate (0.36g) in THF (25ml) was added.
The mixture was stirred for 1 hour and allowed to warm to ambient temperature. Glacial acetic acid (2ml) was added. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography using a 20:1 mixture of ethyl acetate and methanol as eluent. There was thus obtained 2,4'-difluoro-4-[N- (2-hydroxymethyl-7-methyl-4-oxo-3, 4-dihydroquinazolin-6-ylmethyl) - N-(prop-2-ynyl)aminol-a-morpholinosulphonyldesoxybenzoin (0.3g, 782), m.p. 120-1220C.
NIIR Spectrum (CDC13) 2.32 (t, 1H), 2.44 (s, 3H), 3.16 (m, 4H), 3.58 (m, 4H), 4.13 (broad s, 2H), 4.63 (s, 2H), 4.68 (s, 2H), 6.05 (d, 1H), 6.37 (d of d's, 1H), 6.59 (d of d's, 1H), 7.0-8.0 (m, 7H).
Elemental Analysis: Found C, 58.5; H, 5.0; N, 8.3; C32H30F2N406S lH2O requires C, 58.7; H, 4.9; N, 8.5X.
The pentafluorophenyl g-[N-(2-acetoxymethyl-7-methyl-4-oxo- 3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-o-fluoro- benzoate used as a starting material was obtained as follows: A solution of methyl chloroacetimidate in methanol obtained by the addition of sodium (0.2g) to a mixture of chloroacetonitrile (21ml) and methanol (250ml)] was added to a mixture of 4,5-dimethylanthranilic acid hydrochloride (60g; Acta. Chem. Scand., 21, 983) and sodium methoxide solution [obtained by the addition of sodium (7g) to methanol (400ml)]. The mixture was stirred and heated to reflux for 1 hour. The mixture was allowed to cool to ambient temperature. The precipitate was isolated and washed with methanol (500ml) and with water (500ml). There was thus obtained 2-chloromethyl-6,7-dimethyl-3,4-dihydroquinazolin-4-one (90g).
MHR Spectrum (CD3SOCD3) 2.37 (s, 6H), 4.53 (s, 2H), 7.46 (s, 1H), 7.86 (s, 1H).
A mixture of the product so obtained, sodium acetate (120g) and DMF (600ml) was stirred and heated to 800C for 15 minutes. The mixture was cooled to ambient temperature and poured onto ice (1.5kg). The mixture was stirred for 20 minutes. The precipitate was isolated and dried. There was thus obtained 2-acetoxymethyl-6,7dimethyl-3,4-dihydroquinazolin-4-one (46g).
NER Spectrum (CD3SOCD3) 2.14 (s, 3H), 2.36 (s, 6H), 4.93 (s, 2H), 7.43 (s, 1H), 7.85 (s, 1H).
A mixture of a portion (26g) of the material so obtained, N-bromosuccinimide (20g), azobisisobutyronitrile (1.2g), chloroform (500ml) and carbon tetrachloride (100Oml) was stirred and heated to reflux while being irradiated with the light from a 300 watt lamp.
The mixture was cooled to ambient temperature and filtered. The filtrate was evaporated to give 2-acetoxymethyl-6-bromomethyl-7 methyl-3,4-dihydroquinazolin-4-one (27g) which was used without further purification.
The product so obtained was reacted with tert-butyl o-fluoro-E-(prop-2-ynyl)aminobenzoate using analogous procedures to those described in the portion of Example 13 below which is concerned with the preparation of starting materials. There was thus obtained pentafluorophenyl E-(N- (2-acetoxymethyl-7-methyl-4-oxo-3 ,4-dihydro- quinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-o-fluorobenzoate.
NnR Spectrum (CDCl3 + CD3SOCD3) 2.20 (s, 3H), 2.49 (s, 3H), 2.58 (t, 1H), 4.20 (s, 2H), 4.70 (s, 2H), 5.32 (s, 2H), 6.60 (m, 2H), 7.34 (s, 1H), 7.58 (s, 1H), 7.96 (t, 1H).
The p-fluorobenzyl morpholino sulphone used as a starting material was obtained as follows: A solution of (4-fluorophenyl)methanesulphonyl chloride (J.Pharm.Sci., 64, 1961; 10.4g) in methylene chloride (50ml) was added dropwise to a stirred solution of morpholine (9.6g) in methylene chloride (30ml) which had been cooled to 5"C. The mixture was stirred at ambient temperature for 1 hour. The mixture was washed with 2N aqueous hydrochloric acid and with water, dried (MgS04) and evaporated. There was thus obtained the required starting material (12g, 92), m.p. 158-1590C (recrystallised from a 1:1 mixture of hexane and ethyl acetate).
Example 11 Thionyl chloride (0.2ml) was added dropwise to a stirred solution of 2, 4'-difluoro-4- [N-(2-hydroxymethyl-7-methyl-4-oxo-3, 4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-a-morpholino- sulphonyldesoxybenzoin (0.2g) in methylene chloride (10ml). The mixture was stirred at ambient temperature for 3 hours. The mixture was evaporated and the residue was dissolved in a solution of dimethylamine in methanol (30X w/v, 1Oml). The solution was stirred at ambient temperature for 1 hour. The mixture was evaporated and the residue was purified by column chromatography using a 20:1 mixture of chloroform and methanol as eluent.There was thus obtained 2,4' difluoro-4-lN-(2-dimethylaminomethyl-7-methyl-4-oXo-3,4-dihydro- quinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminol-a-morpholinosulphonyl- desoxybenzoin (O.lg, 49), m.p. 1200C.
NHR Spectrum (CDCl3) 2.30 (t, 1H), 2.42 (s, 6H), 2.46 (s, 3H), 3.18 (m, 4H), 3.58 (m, 6H), 4.13 (d, 2H), 4.63 (s, 2H), 6.05 (d, 1H), 6.37 (d of d's, 1H), 6.60 (d of d's, 1H), 7.0-8.0 (m, 7H).
Elemental Analysis: Found C, 60.2; H, 5.4; N, 10.1; C34H35F2N505S 1H20 requires C, 59.9; H, 5.4; N, 10.3I.
Example 12 The procedure described in Example 10 was repeated except that benzyl methyl sulphone was used in place of p-fluorobenzyl morpholino sulphone and that the reaction mixture was cooled initially to -500C for the addition of the n-butyl lithium, warmed to -100C during 30 minutes after the addition of the n-butyl lithium and recooled to -50 C for the addition of the benzoate. There was thus obtained 2-fluoro-4-[N-(2-hydroxymethyl-7-methyl-4-oxo-3,4-dihydro quinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminol- -methylsulphonyl- desoxybenzoin in 98X yield, m.p. 203-205"C.
NHR Spectrum (CD3SOCD3) 2.35 (t, 1H), 2.44 (s, 3H), 3.0 (s, 3H), 4.15 (d, 2H), 4.58 (s, 2H), 4.65 (s, 2H), 5.87 (d, 1H), 6.36 (d of d's, 1H), 6.62 (d of d's, 1H), 7.4-7.9 (m, 8H).
Elemental Analysis: Found C, 61.5; H, 4.6; N, 7.3; C29H26FN305S 1H20 requires C, 61.6; H, 4.9; N, 7.4X.
Example 13 Using an analogous procedure to that described in Example 12, pentafluorophenyl E-[N-(2-acetoxymethy1-7-methyl-4-oxo-3,4 dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoate was reacted with benzyl methyl sulphone to give 4-[N-(2-hydroxymethyl 7-methyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)- amino]-a-methylsulphonyldesoxybenzoin in 252 yield, m.p. 150 0C.
NMR Spectrum (CD3SOCD3) 2.43 (s, 3H), 2.96 (s, 3H), 3.19 (t, 1H), 4.33 (m, 4H), 4.73 (s, 2H), 6.61 (s, 1H), 6.80 (d, 2H), 7.4-8.0 (m, 9H).
Elemental Analysis: Found C, 63.4; H, 5.3; N, 7.6; C29H27N305S 1H20 requires C, 63.6; H, 5.3; N, 7.7%.
The pentafluorophenyl E-[N- (2-acetoxymethyl) -7-methyl-4- oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino] benzoate used as a starting material was obtained as follows: A mixture of 2-acetoxymethyl-6-bromomethyl-7-methyl- 3, 4-dihydroquinazolin-4-one (27g), tert-butyl-E- (prop-2-ynyl)- aminobenzoate (16g), powdered calcium carbonate (lOg) and DMF (200ml) was stirred and heated to 90 C for 16 hours. The hot mixture was filtered and the filtrate was evaporated. The residue was triturated under methylene chloride to give tert-butyl -[N-(2-acetoxy- methyl-7-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N (prop-2-ynyl)amino]benzoate (20g).
NHR Spectrum (CD3SOCD3) 1.51 (s, 9H), 2.12 (s, 3H), 2.46 (s, 3H), 3.18 (t, 1H), 4.31 (d, 2H), 4.71 (s, 2H), 4.92 (s, 2H), 6.80 (d, 2H), 7.50 (s, 1H), 7.72 (d, 2H), 7.75 (s, 1H).
A mixture of a portion (8g) of the material so obtained, trifluoroacetic acid (SOml) and methylene chloride (50ml) was stirred at ambient temperature for 3 hours. The mixture was evaporated and the residue was triturated under diethyl ether. There was thus obtained 2- [N- (2-acetoxymethyl-7-methyl-4-oxo-3, 4-dihydro- quinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminolbenzoic acid (7. 4g).
A mixture of the product so obtained, pentafluorophenol (9g), dicyclohexylcarbodiimide (12g), 4-dimethylaminopyridine (lug) and DMF (loom) was stirred at ambient temperature for 16 hours. The mixture was filtered and the filtrate was evaporated. The residue was triturated under a 4:1 mixture of chloroform and acetone. There was thus obtained pentafluorophenyl E-[N- (2-acetoxymethyl) -7-methyl-4- oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] benzoate (7.3g).
NHR Spectrum (CD3SOCD3) 2.13 (s, 3H), 2.46 (s, 3H), 3.25 (t, 1H), 4.41 (d, 2H), 4.81 (s, 2H), 4.93 (s, 2H), 6.95 (d, 2H), 7.53 (s, 1H), 7.73 (s, 1H), 7.99 (d, 2H).
Example 14 Using an analogous procedure to that described in Example 11, 4-[N-(2-hydroxymethyl-7-methyl-4-oxo-3,4-dihydroquinazolin-6 ylmethyl)-N-(prop-2-ynyl) amino-&alpha;-methylsulphonyldesoxybenzoin was reacted in turn with thionyl chloride and N-methylpiperazine to give 4-[N-[7-methyl-2-(4-methylpiperazin-1-ylmethyl0-4-oxo-3,4-dihydro quinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino}-&alpha;-methylsulphonyl- desoxybenzoin in 45X yield, m.p. 170 C.
NKR Spectrum (CD3SOCD3) 2.24 (s, 3H), 2.44 (s, 3H), 2.97 (s, 3H), 3.19 (t, 1H), 3.26 (m, 8H), 3.40 (s, 2H), 4.34 (s, 2H), 4.73 (s, 2H), 6.61 (s, 1H), 6.80 (d, 2H), 7.6-8.0 (m, 9H).
Elemental Analysis: Found C, 64.8; H, 6.3; N, 11.0; C34H37N504S 1H20 requires C, 64.9; H, 6.2; N, 11.1.
Example 15 A mixture of 4- [N- (2-hydroxymethyl-7-methyl-4-oxo-3, 4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino- -methyl- sulphonyldesoxybenzoin (0.2g), succinic anhydride (O.lg), triethylamine (0.15g) and chloroform (50ml) was stirred at ambient temperature for 2 hours. Glacial acetic acid (0.5ml) was added and the mixture was evaporated. The residue was purified by column chromatography using a 4:1 mixture of chloroform and methanol as eluent. The solid so obtained was dissolved in a 1:1 mixture of methanol and water (50ml) and brought to pH6 by the addition of O.1N aqueous soidum bicarbonate solution. The precipitate was isolated and dried.There was thus obtained the sodium salt of 4-(N-[2-(3- carboxypro;ionyloxymethyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-6 ylmethyl] -N- (prop-2-ynyl)amino) -a-methylsulphonyldesoxybenzoin (O.llg, 36Z).
NER Spectrum (CD3SOCD3) 2.4-2.6 (m, 7H), 2.97 (s, 3H), 4.33 (s, 2H), 4.75 (s, 2H), 4.98 (s, 2H), 6.63 (s, 1H), 6.80 (d, 2H), 7.4-7.9 (m, 9H).
Elemental Analysis: Found C, 56.0; H, 5.2; N, 5.8; C33H30N308SNa 3H20 requires C, 56.2; H, 5.1; N, 6.0%.
Example 16 A solution of g-fluorobenzyl morpholino sulphone (0.43g) in THF (1Oml) was added dropwise to a stirred solution of lithium di-isopropylamide (2H in THF; 0.95ml) in ThF (30ml) which had been cooled to 600 C. The mixture was stirred and allowed to warm to -200C during 15 minutes. The mixture was recooled to -6O0C and a solution of pentafluorophenyl o-fluoro-E-(N-[2, 7-dimethyl-4-oxo-3- (pivaloyloxy- methyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino}benzoate (0.36g) in ThF (lOml) was added. The mixture was allowed to warm to ambient temperature and was stirred for 16 hours.The mixture was poured into a saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x40ml). The combined extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluent. The product so obtained was triturated under diethyl ether. There was thus obtained 2,4-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6 ylmethyl) -N- (prop-2-ynyl) amino] -a-morpholinosulphonyldesoxybenzoin (0.175g, 51X), m.p. 195-197 C.
nIL Spectrum (CD3SOCD3 + CD3C02D) 2.3 (s, 3H), 2.4 (s, 3H), 3.0 (m, 4H), 3.45 (m, 4H), 4.32 (s, 2H), 4.72 (s, 2H), 6.23 (d, 1H), 6.6 (m, 2H), 7.2 (t, 2H), 7.4 (s, 1H), 7.68 (m, 3H), 7.82 (t, 1H).
Elemental Analysis: Found C, 58.5; H, 4.6; N, 8.0; C32H30F2N4O5S 1HCl 0.2(C2H5)20 requires C, 58.6; H, 4.8; N, 8.3%.
Example 17 Using an analogous procedure to that described in Example 16, except that, where necessary, pentafluorophenyl 2-(N-[2,7- dimethyl-4-oxo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6 ylmethyl]-N-(prop-2-ynyl)amino)benzoate was used in place of pentafluorophenyl o-fluoro-- (N- [2, 7-dimethyl-4-oxo-3- (pivaloyloxy- methyl)-3,4-dihydroquinazolin-6-ylmethyll-N-(prop-2-ynyl)amino}- benzoate and, where necessary, the appropriate sulphone was used in place of g-fluorobenzyl morpholino sulphone, there were obtained the quinazoline derivatives described in the following Table, the structures of which were confirmed by proton magnetic resonance and mass spectroscopy and by elemental analysis.
TABLE II
Example 17 Rb Ar2 Q' m.p.
Compound No. ( C) la H 3-pyridyl methyl 190-192 2b F p-fluorophenyl methyl 171-173 3c F p-cyanophenyl methyl 173-174 4d F -fluorophenyl 4-pyridyl 198-199 5 H p-fluorophenyl methyl 163-166 6e 7f F p-tolyl methyl - 8 H -fluorophenyl morpholino 155-158 9g F p-fluorophenyl N-(2-dimethyl- 134-135 aminoethyl)-N - methylamino 10h F p-fluorophenyl 4-tert-butoxy- 142-144 carbonyl piperidin-l-yl lli F 2-pyridyl methyl 12j H p-fluorophenyl dimethylamino 163-165 F 3-pyridyl methyl 173-175 Notes a. The product contained 1 equivalent of water.
The methyl 3-pyridylmethyl sulphone used as a starting material was obtained as follows: Sodium methanethiolate (9.4g) was added to a stirred solution of 3-(chloromethyl)pyridine (lOg) in DMF (50ml) and the mixture was stirred at ambient temperature for 2.5 hours. The mixture was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried (MgS04) and evaporated. There was thus obtained methyl 3-pyridylmethyl sulphide as an oil (5.9g, 70%).
NMR Spectrum (CDC13) 2.02 (s, 3H), 3.67 (s, 2H), 7.26 (m, 1H), 7.67 (m, 1H), 8.53 (m, 2H).
A solution of 3-chloroperoxybenzoic acid (13.5g) in methylene chloride (40ml) was added to a solution of methyl 3-pyridylmethyl sulphide (5.2g) in methylene chloride (40ml) which had been cooled to O"C. The mixture was stirred at OOC to 50C for 1.5 hours. The mixture was evaporated. The residue was basified by the addition of a saturated aqueous sodium bicarbonate solution and the mixture was re-evaporated. The residue was triturated under methylene chloride. There was thus obtained methyl 3-pyridylmethyl sulphone (2.3g. 36X).
nIL Spectrum (CDCl3 + CD3SOCD3) 2.97 (s, 3H), 4.58 (s, 2H), 7.46 (m, 1H), 7.83 (m, 1H), 8.59 (m, 2H).
b. n-Butyl lithium rather than lithium di-isopropylamide was used to generate the lithium salt of -fluorophenyl methyl sulphone.
The product contained 0.2 equivalents of ethyl acetate.
The -fluorobenzyl methyl sulphone used as a starting material was obtained from p-fluorobenzyl chloride using an analogous procedure to that described in Note a. above.
c. The p-cyanobenzyl methyl sulphone used as a starting material was obtained from P-cyanobenzyl bromide using an analogous procedure to that described in Note a. above.
d. The product contained 0.5 equivalents of water.
The -fluorobenzyl 4-pyridyl sulphone used as a starting material was obtained as follows: 4-Mercaptopyridine (1.7g) was added portionwise to a stirred mixture of sodium hydride (60X dispersion in mineral oil, 0.63g) and DHF (l0ml) which had been cooled in an ice-bath. The mixture was stirred at 0 C for 10 minutes. p-Fluorobenzyl chloride (lug) was added dropwise. The mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with water and with brine, dried (ngS04) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluent.There was thus obtained p-fluorobenzyl 4-pyridyl sulphide (1.lug, 72%).
NNR Spectrum (CDC13) 4.19 (s, 2H), 7.03 (m, 2H), 7.13 (d, 2H), 7.35 (m, 2H), 8.41 (broad s, 2H).
The material so obtained was oxidised with 3-chloroperoxybenzoic acid using an analogous procedure to that described in Note a. above. There was thus obtained P-fluorobenzyl 4-pyridyl suiphone.
NR Spectrum (CD3SOCD3) 4.85 (s, 2H), 7.21 (m, 4H), 7.7 (m, 2H), 8.87 (m, 2H).
e. The methyl p-tolyl sulphone used as a starting material was obtained from p-tolyl chloride using an analogous procedure to that described in Note a. above.
f. The reaction mixture was maintained at 50C for 16 hours rather than being allowed to warm to ambient temperature. The product contained 0.5 equivalents of water and 1 equivalent of (C2H5)20 The -fluoro-N,N-dimethyl-a-toluenesulphonamide used as a starting material was obtained as follows: A solution of (4-fluorophenyl)methanesulphonyl chloride (0.5g) in methylene chloride (10ml) was added to a stirred ethanolic solution of dimethylamine (33% in ethanol, Sml) which had been cooled to OOC. The mixture was allowed to warm to ambient temperature and was stirred for 2 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and ethyl acetate as eluent.There was thus obtained -fluoro-N,N-dimethyl-a-toluenesulphonamide (0.25g, 48X).
NMR Spectrum (CDCl3) 2.78 (s, 6H), 4.18 (s, 2H), 7.09 (t, 2H), 7.38 (m, 2H).
g. The reaction mixture was maintained at -20 C for 20 minutes rather than being allowed to warm to ambient temperature for 16 hours.
The product contains 1 equivalent of water and 0.3 equivalents of ethyl acetate.
The 2-fluoro-N-methyl-N-(2-dimethylaminoethyl) -a-toluene- sulphonamide used as a starting material was obtained by the reaction of (4-fluorophenyl)methanesulphonyl chloride and N-methyl-N-(2dimethylaminoethyl)amine using an analogous procedure to that described in Note f. above.
h. The product contained 1 equivalent of water and 0.5 equivalents of ethyl acetate.
The -fluorobenzyl 4-tert-butoxycarbonylpiperazin-1-yl sulphone used as a starting material was obtained by the reaction of (4-fluorophenyl)methanesulphonyl chloride and N-tert-butoxyzarbonyl- piperazine using an analogous procedure to that described in Note f.
above.
i. The product contained 0.5 equivalents of water and gave the following characteristic NMR data: (CD3SOCD3+CD3C02D) 2.37 (s, 3H), 2.50 (s, 3H), 3.09 (s, 1H), 3.40 (s, 3K), 4.50 (s, 2H), 4.91 (s, 2H), 7.09 (t, 1H), 7.21 (d, 1H), 7.51 (d, 2H), 7.70 (m, 1H), 7.82 (s, 1H), 8.24 (d, 1H), 8.99 (d, 1H), 9.14 (d, 1H).
The methyl 2-pyridylmethyl sulphone used as a starting material was obtained from 2-(chloromethyl)pyridine using an analogous procedure to that described in Note a. above.
j. n-Butyl lithium rather than lithium di-isopropylamide was used to generate the lithium salt of methyl 3-pyridylmethyl sulphone.
The product was further purified by reverse-phase column chromatography using decreasingly polar mixtures of water and methanol which was acidified with trifluoroacetic acid. The product contained 1.5 equivalents of water and 1 equivalent of trifluoroacetic acid.
Example 18 A solution of -fluoro-N,N-dimethyl-a-toluenesulphonamide (1.87g) in ThF (50ml) was added dropwise to a stirred solution of lithium di-isopropylamide (2N in THF, 4.7ml) in THF (1O0ml) which had been cooled to -60 C. The mixture was stirred and allowed to warm to -20 C for 15 minutes. The mixture was recooled to -600C and a solution of pentafluorophenyl o-fluoro-E-(N-[2, 7-dimethyl-4-oxo-3 (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyll-N-(prop-2-ynyl)- amino)benzoate (1.4g) in THF (50ml) was added. The mixture was allowed to warm to ambient temperature and was stirred for 16 hours.
The mixture was poured into a saturated aqueous ammonium chloride solution and extracted with ethyl acetate (2x150ml). The combined extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluent. There was thus obtained N,N-dimethyl-P-fluoro-&alpha;-(o-fluoro-p-(N-[2,7-dimethyl-4-oxo-3- (pivaloyloxymethyl0-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino)benzoyl)-x-toluenesulphonamide as a solid (0.55g, 43X).
NMR Spectrum (CD3SOCD3) 1.12 (s, 9H), 2.43 (s, 3H), 2.58 (s, 3H), 2.60 (s, 6H), 3.26 (s, 1H), 4.37 (s, 2H), 4.77 (s, 2H), 5.98 (s, 2H), 6.28 (d, 1H), 6.62 (m, 2H), 7.24 (t, 2H), 7.48 (s, 1H), 7.70 (m, 2H), 7.84 (t, 1H).
A mixture of 2N aqueous hydrochloric acid (4ml) and a solution of a portion (O.lg) of the product so obtained in ethyl acetate (8ml) was stirred and heated to reflux for 16 hours. The mixture was cooled to ambient temperature, neutralised by the addition of sodium bicarbonate and extracted with ethyl acetate (2x20ml). The combined extracts were washed with brine, dried (MgS04) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluent.
The product so obtained was triturated under diethyl ether. There was thus obtained N,N-dimethyl-2-fluoro-a-{o-fluoro-E-lN-(2,7-dimethyl-4- oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino] benzoyl]-&alpha;- toluenesulphonamide (0.064g, 76%), m.p. 198-199"C.
NMR Spectrum (CD3SOCD3) 2.34 (s, 3H), 2.44 (s, 3H), 2.63 (s, 6H), 3.27 (s, 1H), 4.37 (s, 2H), 4.77 (s, 2H), 6.31 (d, 1H), 6.66 (m, 2H), 7.25 (t, 2H), 7.44 (s, 1H), 7.69 (m, 3H), 7.86 (t, 1H).
Elemental Analysis: Found C, 60.4; H, 4.9; N, 8.8; C30H28F2N404S lH20 0.2EtOAc requires C, 60.2; H, 5.1; N, 9.1%.
Example 19 Using analogous procedures to those described in Example 18, pentafluorophenyl p-[N-[2-methyl-4-oxo-3-(pivaloyloxymethyl)-3,4 dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino} benzoate was reacted with 2-fluorobenzyl methyl sulphone to give 4'-fluoro-4-[N (2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2 amino]-a-methylsulphonyldesoxybenzoin in 222 yield, m.p. 133-1350C.
NER Spectrum (CD3SOCD3) 2.37 (s, 3H), 2.98 (s, 3H), 3.25 (s, 1H), 4.40 (s, 2H), 4.34 (s, 2H), 6.68 (s, 1H), 6.85 (d, 2H), 7.27 (t, 2H), 7.53 (d, 1H), 7.68 (m, 3H), 7.94 (d, 2H).
Elemental Analysis: Found C, 63.7; H, 5.1; N, 7.0; C28H24FN304S 0.3H20 O.5EtOAc requires C, 63.5; H, 5.0; N, 7.4X.
Example 20 Using an analogous procedure to that described in Example 16, pentafluorophenyl o-fluoro-2- (N- [2-methyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino)benzoate was reacted with p-fluorobenzyl methyl sulphone to give 2,4'-difluoro-4-[N-(2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl) N-(prop-2-ynyl) amino]-&alpha;-methylsulphonyldesoxybenzoin in 27X yield, m.p. 111-113 C.
NER Spectrum (CD3SOCD3+CD3C02D) 2.37 (s, 3H), 3.0 (s, 3H), 3.11 (s, 1H), 4.41 (s, 2H), 4.88 (s, 2H), 6.20 (s, 1H), 6.66 (m, 2H), 7.24 (t, 2H), 7.62 (m, 4H), 7.86 (t, 1H), 7.98 (d, 1H).
Elemental Analysis: Found C, 60.9; H, 4.5; N, 7.3; C28H23F2N3O4S 0.81120 0.3EtOAc requires C, 60.8; H, 4.7; N, 7.2.
The pentafluorophenyl o-fluoro-2- (N- [2-methyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino)benzoate used as a starting material was obtained by the reaction of o-fluoro-p-{N-[2-methyl-4-oxo-3-(pivaloyloxymethyl)-3,4dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino} benzoic acid (European Patent Application No. 0459730, Example 13 thereof) and pentafluorophenol using an analogous procedure to that mentioned in the portion of Example 4 which is concerned with the preparation of starting materials.
Example 21 Using an analogous procedure to that described in Example 16, pentafluorophenyl o-fluoro-E-(N-[2-methyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl)amino)benzoate was reacted with benzyl methyl sulphone to give 2-fluoro-4-[N-(2-methyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N- (prop-2-ynyl)amino] -a-methylsulphonyldesoxybenzoin in 31Z yield, m. p.
106-1080C.
NER Spectrum (CD3SOCD3) 2.38 (s, 3H), 3.0 (s, 3H), 3.11 (s, 1H), 4.37 (s, 2H), 4.85 (s, 2H), 6.16 (s, 1H), 6.52-6.75 (m, 2H), 7.43 (m, 3H), 7.56 (m, 3H), 7.66 (m, 1H), 7.85 (t, 1H), 7.97 (s, 1H).
Elemental Analysis: Found C, 62.0; H, 4.6; N, 8.1; C28H24FN304S 1H20 0.2EtOAc requires C, 62.5; H, 5.2; N, 7.6X.
Example 22 A mixture of 2,4'-difluoro-4-[N-(2,7-dimethyl-4-oxo-3,4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino]-&alpha;-(4-tert- butoxycarbonylpiperazin-1-ylsulphonyl)desoxybenzoin (0.29g) and trifluoroacetic acid (5ml) was stirred at ambient temperature for 25 minutes. The mixture was evaporated and the residue was triturated under diethyl ether. There was thus obtained 2,4'-difluoro-4-[N-(2,7dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino] -a-(piperazin-1-ylsulphonyl)desoxybenzoin (0.26g), m. p.
151-153 C.
NMR Spectrum (CD3SOCD3 + CD3OD) 2.38 (s, 3H), 2.43 (s, 3H), 2.95-3.09 (m, 2H), 3.28 (m, 2H), 4.36 (s, 2H), 4.77 (s, 2H), 6.28 (s, 1H), 6.58 (m, 2H), 7.20 (t, 2H), 7.46 (s, 1H), 7.62 (m, 3H), 7.82 (s, 1H).
Elemental Analysis: Found C, 49.5; H, 4.2; N, 7.7; C32H31F2N504S 2.3CF3C02H requires C, 49.8; H, 3.8; N, 7.92.
Example 23 n-Butyl lithium (1.6M in hexane, 0.82ml) was added dropwise to a stirred solution of -fluorobenzyl methyl sulphone (0.23g) in THF (22ml) which had been cooled to -70 C. The mixture was stirred and allowed to warm to -30 C during 1 hour. The mixture was recooled to -70 C and a solution of methyl 5-{N-12,7-dimethyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino)pyridine-2-carboxylate (0.2g) in THF (12ml) was added. The mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The mixture was poured into a saturated aqueous ammonium chloride solution and extracted with ethyl acetate.The organic extract was washed with brine, dried (HgS04) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluent. There was thus obtained 5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N (prop-2-ynyl) amino] pyrid-2-yl p-fluoro-&alpha;-methylsulphonylbenzyl ketone (0.14g, 64Z), m.p. 154-159 C.
NMR Spectrum (CD3SOCD3) 2.32 (s, 3H), 2.45 (s, 3H), 2.99 (s, 3H), 4.47 (s, 2H), 4.85 (s, 2H), 7.1 (s, 1H), 7.2-8.2 (m, 9H), 12.1 (broad s, 1H).
Elemental Analysis: Found C, 63.3; H, 5.2; N, 9.6; C281125FN4O4S requires C, 63.1; H, 5.1; N, 9.6%.
The methyl 5-{N-[2,7-dimethyl-4-oxo-3-(pivaloyloxymethyl) 3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino} pyridine-2carboxylate used as a starting material was obtained as follows: A mixture of 6-bromomethyl-2, 7-dimethyl-3-(pivaloyloxy- methyl)-3,4-dihydroquinazolin-4-one (1. llg), methyl 5-[N-(prop-2-ynyl) amino] pyridine-2-carboxylate [0.61g; obtained in quantitative yield by treating methyl 5-[N-tert-butoxycarbonyl) -N-(prop-2-ynyl) amino]pyridine-2-carboxylate (J. Med. Chem., 1991, 1594) with trifluoroacetic acid at 0 C for 1 hour], 2,6-lutidine (0.62g), sodium iodide (0.005g) and DMA (20ml) was stirred and heated to 950C for 7 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and a 2N aqueous hydrochloric acid solution.
The acidity of the aqueous layer was reduced to pH4 by the addition of 2N aqueous sodium hydroxide solution and the solution was extracted with ethyl acetate. The organic layer was dried (MgS04) and evaporated. The residue was purified by column chromatography using ethyl acetate as eluent. There was thus obtained methyl 5-(N-[2,7- dimethyl-4-oxo-3-(pivaloyloxymethyl)-3,4-dihydroquinazolin-6 ylmethyl] -N- (prop-2-ynyl) amino) pyridine-2-carboxylate as a gum (0.262g).
nIL Spectrum (CD3SOCD3) 1.15 (s, 9H), 2.57 (s, 3H), 3.80 (s, 3H), 4.40 (d, 2H), 4.80 (s, 2H), 6.0 (s, 2H), 7.22 (m, 1H), 7.48 (s, 1H), 7.75 (s, 1H), 7.88 (d, 1H), 8.21 (d, 1H).
Example 24 Using an analogous procedure to that described in Example 23, methyl 5-{N-2,7-dimethyl-4-oxo-3-(pivaloyloxymethyl)-3,4 dihydroquinazolin-6-ylmethyl] -N- (prop-2-ynyl)amino)pyridine-2- carboxylate was reacted with p-fluoro-N,N-dimethyl- -toluene- sulphonamide to give a-{5-lN-(2,7-dimethyl-4-oxo-3,4-dihydro- quinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino] pyridine-2-carbonyl}-p N,N-dimethyl-a-toluenesulphonamide in 33% yield, m.p. 146-151"C.
NNR Spectrum (CD3SOCD3) 2.3 (s, 3H), 2.44 (s, 3H), 2.62 (s, 6H), 4.45 (s, 2H), 4.83 (s, 2H), 7.2-8.25 (m, 10H), 12.1 (broad s, 1H).
Elemental Analysis: Found C, 59.8; H, 5.1; N, 11.3; C29H28FN504S 1.3H20 requires C, 59.4; H, 5.2; N, 11.91.
Example 25 Lithium di-isopropylamide (1.5H in cyclohexane, 0.8ml) was added dropwise to a stirred solution of methyl 3-pyridylmethyl sulphone (0.204g) in THF (30ml) which had been cooled to -50 C. The mixture was allowed to warm to -300C during 30 minutes. The mixture was recooled to -600C and a solution of pentafluorophenyl 5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl-N-(prop-2 ynyl)aminoipyridine-2-carboxylate (0.14g) in DMA (5ml) was added. The mixture was stirred during 4 hours, the temperature being allowed to rise to 200 C. The mixture was poured into a saturated aqueous ammonium chloride solution and extracted with ethyl acetate.The organic extract was washed with brine, dried (MgSO4) and evaporated.
The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluent. The material so obtained was further purified by reverse-phase column chromatography using as eluent decreasingly polar mixtures of water and methanol which had been acidified with a small quantity of acetic acid. There was thus obtained 5-[N-(2,7-dimethyl-4-oxo-3,4-dihydro quinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminolpyrid-2-yl 1-methylsulphonyl-1-(3-pyridyl)methyl ketone (0.035g, 26Z), m. p.
160-164"C.
NEIR Spectrum (CD3SOCD3) 2.31 (s, 3H), 2.45 (s, 3H), 3.03 (s, 3H), 4.45 (s, 2H), 4.83 (s, 2H), 7.15-8.77 (m, 10H), 12.05 (s, 1H).
Elemental Analysis: Found C, 59.3; H, 5.2; N, 11.6; C27H25N5O4S 1H20 lCH3CO2H requires C, 58.5; H, 5.1; N, 11.8X.
The pentafluorophenyl 5-[EF(2, 7-dimethyl-4-oxo-3, 4- dihydroquinazolin-6-ylmethyl) -N- (prop-2-ynyl) aminoj pyridine-2- carboxylate used as a starting material was obtained as follows: A mixture of methyl 5-(N-[2, 7-dimethyl-4-oxo-3- (pivaloyloxymethyl)-3,4-dihydroquinazolin-6-ylmethyl]-N-(prop-2-ynyl) amino)pyridine-2-carboxylate (0.26g), 2N aqueous sodium hydroxide solution (20ml) and methanol (lOml) was stirred at ambient temperature for 16 hours. The bulk of the methanol was evaporated and the residual aqueous solution was acidified to pH4 by the addition of 2N aqueous hydrochloric acid. The resultant precipitate was isolated, washed in turn with water and diethyl ether and dried.There was thus obtained 5-lN-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N- (prop-2-ynyl)amino]pyridine-2-carboxylic acid (0.143g).
After appropriate repetition of the preceding reaction, the carboxylic acid (0.75g) so obtained was dissolved in DMA (10ml). The solution was cooled to 100C and pyridine (0.49ml) and pentafluorophenyl trifluoroacetate (1.06ml; prepared by the reaction of pentafluorophenol and trifluoroacetic acid) were added in turn.
The mixture was stirred for 2 hours and allowed to warm to ambient temperature. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was dried (MgS04) and evaporated. The residue was purified by column chromatography using ethyl acetate as eluent. There was thus obtained pentafluorophenyl 5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylmethyl)-N-(prop-2-ynyl)aminolpyridine-2-carboxylate (0.82g).
NMR Spectrum (CD3SOCD3) 2.33 (s, 3H), 2.46 (s, 3H), 4.50 (d, 2H), 4.87 (s, 2H), 7.25-8.35 (m, 5H), 12.10 (broad s, 1H).
Example 26 The procedure described in Example 25 was repeated except that p-fluorobenzyl 4-pyridyl sulphone was used in place of methyl 3-pyridylmethyl sulphone. There was thus obtained 5-[N-(2,7-dimethyl4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino] pyrid-2yl -fluoro- -(4-pyridylsulphonyl)benzyl ketone in 31X yield, m.p.
158-1620C.
NMR Spectrum (CDCl3) 2.32 (m, 1H), 2.48 (2 s's, 6H), 4.22 (d, 2H), 4.69 (s, 2H), 6.95-8.75 (m, 14H).
Elemental Analysis: Found C, 62.7; H, 4.9; N, 10.1; C32H26FN504S 1.2H20 requires C, 62.3; H, 4.6; N, 11.3%.
Example 27 The procedure described in Example 25 was repeated except that N,N-dimethyl-3-pyridylmethanesulphonamide was used in place of methyl 3-pyridylmethyl sulphone. There was thus obtained 5-[N-(2,7 dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)- aminoi pyrid-2-yl 1- (N,N-dimethylsulphamoyl) -1- (3-pyridyl)methyl ketone in 81X yield, m.p. 155-160 C.
NMR Spectrum (CD3SOCD3) 2.22 (s, 3H), 2.35 (s, 3H), 2.54 (s, 6H), 4.39 (d, 2H), 4.76 (s, 2H), 7.2-8.7 (m, lox), 12.0 (broad s, 1H).
Elemental Analysis: Found C, 60.6; H, 5.2; N, 14.9; C28H28N604S 0.5H20 requires C, 60.7; H, 5.3; N, 15.2.
The N,N-dimethyl-3-pyridylmethanesulphonamide used as a starting material was obtained as follows: A mixture of 3-(chloromethyl)pyridine hydrochloride (15g), potassium thioacetate (24g) and acetone (220ml) was stirred at ambient temperature for 22 hours. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography to give 3-(acetylthiomethyl)pyridine (14.lg, 92).
A portion (6.6g) of the material so obtained and sodium acetate (12g) were dissolved in a mixture of glacial acetic acid (140ml) and water (30ml). The mixture was cooled to 100C. Chlorine gas (14g) was passed into the solution. The mixture was evaporated and the residue was triturated under ethyl acetate. There was thus obtained 3-pyridylmethanesulphonyl chloride which was used without further purification.
NHR Spectrum (CD3SOCD3) 4.0 (s, 2H), 8.04 (m, 1H), 8.55 (d, 1H), 8.80 (m, 2H).
The material so obtained was dissolved in THF (200ml) and the solution was stirred and cooled in an ice-bath while dimethylamine gas was led into the solution. When the exothermic reaction ceased, the mixture was stirred at ambient temperature for 1.5 hours. Ethyl acetate was added and the mixture was filtered. The filtrate was evaporated and the residue was purified by column chromatography to give N,N-dimethyl-3-pyridylmethanesulphonamide (1. 96g), m. p. 96-97 C.
NMR Spectrum (CD3SOCD3) 2.75 (s, 6H), 4.50 (s, 2H), 7.42 (m, 1H), 7.83 (m, 1H), 8.58 (m, 2H).
Example 28 The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans: (a) Tablet I mg/tablet Compound X....................................100 Lactose Ph.Eur...............................182.75 Croscarmellose sodium......................... 12.0 Maize starch paste (5 w/v paste) 2.25 Magnesiumwstearate 3.0 (b) Tablet II mg/tablet Compound X.................................... 50 Lactose Ph.Eur................................223.75 Croscarmellose sodium......................... 6.0 Maize starch.................................. 15.0 Polyvinylpyrrolidone (5% w/v paste) 2.25 Magnesium stearate........................... 3.0 (c) Tablet III mg/tablet Compound X.................................... 1.0 Lactose Ph.Eur................................ 93.25 Croscarmellose sodium......................... 4.0 Maize starch paste (5% w/v paste) 0.75 Hagnesium stearate 1.0 (d) Capsule mg/capsule Compound X................................... 10 mg Lactose Ph.Eur ........................... 488.5 Hagnesium stearate ....................... 1.5 (e) Injection I (50 mg/ml) Compound X ............................ 5.0% w/v 1M Sodium hydroxide solution.................. 15.0% v/v 0.1M Hydrochloric acid (to adjust pH to 7.6) Polyethylene glycol 400...................... 4.5% w/v Vater for injection to 100 (f) Injection II (10 mg/ml) Compound X................................... 1.0% w/v Sodium phosphate BP ....................... 3.6X w/v 0.1M Sodium hydroxide solution............... 15.0% v/v Water for injection to 100 (g) Injection III (lmg/ml,buffered to pH6) Compound X ............................... 0.1X w/v Sodium phosphate BP ...................... 2.26X w/v Citric acid ........................... 0.38Z w/v Polyethylene glycol 400 ................... 3.5% w/v Water for injection to 100% The above formulations may be obtained by -conventional procedures well known in the pharmaceutical art. The tablets (a) to (c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
CHEMICAL FORMULAE

Claims (10)

  1. CLAIMS 1. A quinazoline derivative of the formula I
    wherein R1 is hydrogen, amino, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C) alkyl] amino, piperidino, morpholino, piperazin-1-yl, 4-[(1-4C)alkyl]piperazin-1-yl, 4-[(2-4C)alkanoyl]piperazin-l-yl, hydroxy-( 1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C) alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-( 1-4C)alkyl,
    4-[(1-4C)alkyl]piperazin-1-yl-(1-4C)alkyl, 4-[(2-4C) alkanoyl] piperazin-1-yl-(1-4C) alkyl N-[hydroxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-[hydroxy-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[hydroxy-(2-4C)alkyllamino-(1-4C)alkyl, N-[(1-4C)alkoxy-(2-4C)alkyl]amino-(1-4C)alkyl, N-l(1-4C)alkoxy-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-](1-4C) alkoxy-(2-4C) alkyl] amino-(1-4C) alkyl, N-l(1-4C)alkylamino-(2-4C)alkyl]amino-(1-4C)alkyl, N-l(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[(1-4C) alkylamino-(2-4C) alkyl amino-(1-4C) alkyl, N-[di-(1-4C) alkylamino-(2-4C) alkyl] amino-(1-4C) alkyl, N-[di-(1-4C)alkylamino-(2-4C)alkyl]-N-(1-4C)alkylamino-(1-4C)alkyl, N,N-di-[di-(1-4C) alkyloamino-(2-4C) alkyl] amino-(1-4C) alkyl, (2-4C) alkanoyloxy-(1-4C) alkyl, carboxy-(2-4C) alkanoyloxy-(1-4C) alkyl, (1-4C)alkoxycarbonyl-(2-4C)alkanoyloxy-(1-4C)alkyl, hydroxy (2-4C) alkoxy-(1-4C) alkyl or (1-4C) alkoxy-(2-4C) alkoxy-(1-4C) alkyl; the quinazoline ring may optionally bear at the 5-, 7- or 8-position one further substituent selected from halogeno, (1-4C)alkyl and (1-4C) alkoxy; R2 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, hydroxy (2-4C)alkyl, halogeno-(2-4C)alkyl or cyano-(1-4C)alkyl; Arl is phenylene or a 5- or 6-membered aromatic heterocyclene ring which contains up to 3 heteroatoms selected from nitrogen and sulphur, each of which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy;; Ar2 is phenyl or heteroaryl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, (1-4C)alkyl and (1-4C)alkoxy; and Q is nitro, cyano, carbamoyl, sulphamoyl, (1-4C)alkoxycarbonyl, di-[ (1-4C)alkoxyjphosphoryl, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C) alkylsulphonyl, phenylthio, phenylsulphinyl, phenylsulphonyl, phenyl- ( 1-4C)alkylthio, phenyl-(1-4C)alkylsulphinyl, phenyl-(1-4C)- alkylsuiphonyl, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, heteroaryl-(l-4C)alkylthio, heteroaryl- ( 1-4C)alkylsulphinyl, heteroaryl- ( 1-4C)alkylsulphonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyllcarbamoyl, -N-(1-4C)alkylsulphamoyl, N,N-di-1(1-4C)alkyl]sulphamoyl, morpholinosulphonyl, piperidinosulphonyl, piperazin-l-ylsulphonyl or 4-(1-4C)alkylpiperazin-1-ylsulphonyl, and when Q is a group comprising a phenyl or heteroaryl group, said phenyl or heteroaryl group may optionally bear one substituent selected from halogeno, cyano, hydroxy, amino, (1-4C) alkyl and (1-4C) alkoxy; and wherein the theteroaryl group when Ar is heteroaryl, or the heteroaryl group when Q is a heteroaryl-containing group, is a 5- or 6-membered heteroaryl ring which contains 1 or 2 nitrogen heteroatoms and optionally contains a further heteroatom selected from nitrogen, oxygen and sulphur; or a pharmaceutically-acceptable salt thereof.
  2. 2. A quinazoline derivative of the formula I as defined in claim 1 wherein, in addition, Q is 4-(1-4C)alkoxycarbonylpiperazin-1 ylsulphonyl, N-[amino-(2-4C)alkyllsulphamoyl, N-[(1-4C)alkylamino-(2-4C)alkyllsulphamoyl, N-{di-[(1-4C)alkyllamino- (2-4C)alkyl)sulphamoyl, N-(1-4C)alkyl-N-[amino-(2-4C)alkyllsulphamoyl, N-(1-4C)alkyl-N-[ (14C)alkylamino-(2-4C)alkylisulphamoyl or N-(1-4C)alkyl-N-{di-[(1-4C)alkyllamino-(2-4C)alkyl}sulphamoyl; or a pharmaceutically-acceptable salt thereof.
  3. 3. A quinazoline derivative of the formula I as claimed in claim 1 wherein R1 is methyl, hydroxymethyl, methoxymethyl, methylaminomethyl, dimethylaminomethyl, piperidinomethyl, morpholinomethyl, piperazin-l-ylmethyl or 4-methylpiperazin-1-ylmethyl; the quinazoline ring may optionally bear a 7-fluoro, 7-chloro or 7-methyl substituent; R2 is methyl, ethyl, propyl, prop-2-enyl or prop-2-ynyl; Ar1 is 1,4-phenylene which may optionally bear one fluoro substituent, or Ar is thiophene-2,5-diyl or thiazole-2,5-diyl with the group -CO-CH(Ar2)(Q) in the 2-position; Ar2 is phenyl which may optionally bear a substituent selected from fluoro, chloro, nitro, trifluoromethyl or methyl; and Q is nitro, cyano, carbamoyl, sulphamoyl, methoxycarbonyl, ethoxycarbonyl, dimethoxyphosphoryl, diethoxyphosphoryl, methylsulphinyl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphinyl, phenylsulphonyl, benzylsulphinyl, benzylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-methylsulphamoyl, N,Ndimethylsulphamoyl or morpholinosulphonyl; or a pharmaceutically-acceptable salt thereof.
  4. 4. A quinazoline derivative of the formula I as claimed in claim 1 or claim 2 wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group -CO-CH(Ar) (Q) in the 1-positio) or pyridine-2,5-diyl (with the group -CO-CH (Ar) (Q) in the 2-position); Ar2 is phenyl, 3-fluorophenyl, 4-fluorophenyl, 3-nitrophenyl, 4-cyanophenyl, 2-pyridyl or 3-pyridyl; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl, 4-pyridylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl, morpholinosulphonyl, piperazin- 1-ylsulphonyl or N-methyl-N- (2-dimethylaminoethyl) sulphamoyl; or a pharmaceutically-acceptable salt thereof.
  5. 5. A quinazoline derivative of the formula I as claimed in claim 1 or claim 2 wherein R1 is methyl; the quinazoline ring may optionally bear a 7-methyl substituent; R2 is methyl or prop-2-ynyl; Ar is 1,4-phenylene, 2-fluoro-1,4-phenylene (with the group -CO-CH(Ar)(Q) in the 1-position) or pyridine-2,5-diyl (with the group -CO-CH(Ar2)(Q) in the 2-position); Ar2 is phenyl, 3-fluorophenyl, 4-fluorophenyl or 3-pyridyl; and Q is diethoxyphosphoryl, isopropylsulphinyl, methylsulphonyl, isopropylsulphonyl, phenylsulphonyl, benzylsulphonyl, 4-pyridylsulphonyl, N-methylsulphamoyl, N,N-dimethylsulphamoyl or morpholinosulphonyl; or a pharmaceutically-acceptable salt thereof.
  6. 6. A quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in claim 1, selected from: 4-[N-(2-methyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl)amino]-a-methylsulphonyldesoxybenzoin, 4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2 ynyl)amino]-a-methylsulphonyldesoxybenzoin and N,N-dimethyl- -{p-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylmethyl)-N-(prop-2-ynyl)aminolbenzoyl}-a-toluenesulphonamide
  7. 7.A quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in claim 1 or claim 2, selected from: 4-lN-(2,7-dimethyl-4-oXo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2- ynyl) amino ) -ar- isopropylsulphonyldesoxybenzoin , N,N-dimethyl-p-fluoro-a-{p-lN-(2,7-dimethyl-4-oXo-3,4-dihydro- qüinazolin-6-ylmethyl)-N-(prop-2-ynyl)aminolbenzoyl}-a- toluenesulphonamide, 2, 4'-difluoro-4- [N-(2, 7-dimethyl-4-oxo-3 '4- dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino]-&alpha;-methylsulphonyl- desoxybenzoin, N,N-dimethyl-p-fluoro-a-{o-fluoro-E-[N-(2,7-dimethyl-4- oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl) amino] benzoyl}-&alpha;;- toluenesulphonamide, 4'-fluoro-4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl) N-(prop-2-ynyl)amino]-a-methylsulphonyldesoxybenzoin, 2,4t-difluoro-4-lN-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6- ylemthyl)-N-(prop-2-ynyl) amino]-&alpha;-morpholinosulphonyldesoxybenzoin, &alpha;-{5-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(prop 2-ynyl)amino]pyridine-2-carbonyl}-p-fluoro-N,N-dimethyl-a- toluenesulphonamide and 4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N (prop-2-ynyl)amino]phenyl 1-methylsulphonyl-1-(3-pyridyl)methyl ketone.
  8. 8. A process for the preparation of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 which comprises: (a) the reaction of an acid of the formula II
    or a reactive derivative thereof, wherein R is hydrogen or a protecting group, with a compound of the formula Ar-CH2-Q; (b) the reaction of a compound of the formula III
    wherein R has the meaning defined above and Z is a displaceable group, with an amine of the formula:: HNR2-Ar1-C0-CH(Ar2 )(o) (c) for the production of a compound of the formula I wherein Q is a group which comprises a sulphinyl or sulphonyl group, the oxidation of the corresponding compound of the formula I wherein Q is a group which comprises a thio group; (d) for the production of a compound of the formula I wherein R is amino-(1-4C)alkyl or substituted-amino-(l-4C)alkyl, the reaction of a compound of the formula I wherein R1 is hydroxy-(l-4C)alkyl, or a reactive derivative thereof, with ammonia or a substituted-amine;; (e) for the production of a compound of the formula I wherein R is (2-4C)alkanoyloxy-(l-4C)alkyl or substituted-(2-4C)alkanoyloxy (l-4C)alkyl, the reaction of a compound of the formula I wherein R1 is hydroxy-(l-4C)alkyl with an acylating reagent; and (f) for the production of a compound of the formula I wherein Q is a piperazin-l-ylsulphonyl group, the cleavage of a compound of the formula I wherein Q is a 4-(l-4C)alkoxycarbonylpiperazin-l-yl group; and when a pharmaceutically-acceptable salt of a compound of the formula I is required, it may be obtained by reaction of said compound with a suitable acid or base using a conventional procedure; and when an optically active form of a compound of the formula I is required, it may be obtained by carring out one of the aforesaid processes using an optically active starting material, or by resolution of a racemic form of said compound using a conventional procedure.
  9. 9. A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 in association with a pharmaceutically-acceptable diluent or carrier.
  10. 10. The use of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 7 in the manufacture of a novel medicament for use in the production of an anti-tumour effect in a warm-blooded animal.
GB9320077A 1992-09-30 1993-09-29 Quinazoline derivatives Withdrawn GB2271111A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX9306034A MX9306034A (en) 1992-09-30 1993-09-29 QUINAZOLINE DERIVATIVES.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929220571A GB9220571D0 (en) 1992-09-30 1992-09-30 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
GB9320077D0 GB9320077D0 (en) 1993-11-17
GB2271111A true GB2271111A (en) 1994-04-06

Family

ID=10722718

Family Applications (2)

Application Number Title Priority Date Filing Date
GB929220571A Pending GB9220571D0 (en) 1992-09-30 1992-09-30 Quinazoline derivatives
GB9320077A Withdrawn GB2271111A (en) 1992-09-30 1993-09-29 Quinazoline derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB929220571A Pending GB9220571D0 (en) 1992-09-30 1992-09-30 Quinazoline derivatives

Country Status (5)

Country Link
AU (1) AU4829793A (en)
GB (2) GB9220571D0 (en)
IL (1) IL107028A0 (en)
WO (1) WO1994007869A1 (en)
ZA (1) ZA936768B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009158A1 (en) * 1993-09-29 1995-04-06 Zeneca Limited Tricyclic derivatives
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
CN1275596C (en) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 Application of probuco monoester intreating amgiocardiopathy and inflammatry disease
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
JP2010522762A (en) 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー Method for the treatment of diabetes and composition of probucol derivatives
EP3581567A1 (en) 2011-04-10 2019-12-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316657A1 (en) * 1987-11-03 1989-05-24 Warner-Lambert Company Substituted quinazolinones as anticancer agents
EP0365763A1 (en) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Antiproliferative cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0316657A1 (en) * 1987-11-03 1989-05-24 Warner-Lambert Company Substituted quinazolinones as anticancer agents
EP0365763A1 (en) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Antiproliferative cyclic compounds

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009158A1 (en) * 1993-09-29 1995-04-06 Zeneca Limited Tricyclic derivatives
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6562831B1 (en) 1999-10-27 2003-05-13 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6630479B1 (en) 1999-10-27 2003-10-07 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6831085B1 (en) 1999-10-27 2004-12-14 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer

Also Published As

Publication number Publication date
WO1994007869A1 (en) 1994-04-14
AU4829793A (en) 1994-04-26
GB9220571D0 (en) 1992-11-11
GB9320077D0 (en) 1993-11-17
IL107028A0 (en) 1993-12-28
ZA936768B (en) 1994-03-30

Similar Documents

Publication Publication Date Title
RU2111209C1 (en) Quinazoline derivatives, method of their synthesis and pharmaceutical composition based on thereof
AU640016B2 (en) Hydroquinazoline derivatives
EP0373891B1 (en) Anti-tumour agents
AU699163B2 (en) Quinazoline derivatives
EP1274692B1 (en) Quinazoline compounds
US5081124A (en) Method of producing antitumor effect using quinazolin-4-one derivatives
EP0284338B1 (en) Anti-tumour agents
US5187167A (en) Pharmaceutical compositions comprising quinazolin-4-one derivatives
CZ20021008A3 (en) Quinazoline derivatives, process of their preparation and pharmaceutical preparation in which they are comprised
WO1996033977A1 (en) Quinazoline derivatives
EP0318225B1 (en) 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents
GB2271111A (en) Quinazoline derivatives
EP0339976B1 (en) Anti-tumour agents
EP0365763A1 (en) Antiproliferative cyclic compounds
WO1995009158A1 (en) Tricyclic derivatives
US5252573A (en) Anti-tumor agents

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)